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Bioequivalence studies are an essential part of the evaluation of generic drugs. The 
most common in-vivo bioequivalence (BE) study design is the two-period two-
treatment crossover design. AUC (area under the concentration-time curve) and Cmax 
(maximum concentration) are obtained from the observed concentration-time profiles 
for each subject from each treatment under each sequence.  
In the BE evaluation of pharmacokinetic crossover studies, the normality of the 
univariate response variable, e.g.  log(AUC) or log(Cmax) is often assumed in the 
literature without much evidence. Therefore, we investigate the distributional 
assumption of the normality of response variables, log(AUC), log(Cmax), and 
log(Tmax) by simulating concentration-time profiles from the two-stage 
pharmacokinetic models for a wide range of pharmacokinetic parameters and 
measurement error structures. Our simulation shows that log(AUC) has heavy tails 
and log(Cmax) is skewed. We study the impact of the non-normality of response 
variable on the sample size and type I error rate. 
Under the normality of the response variable, the most common approach to testing 
for bioequivalence is the two one-sided tests procedure. We develop the exact 
analytical formula for the probability of rejection in the two one-sided tests procedure 
  
for crossover bioequivalence studies under general parameter settings. Our exact 
formulas for power and sample size are shown to improve in realistic parameter 
settings over the previous approximations.  
We propose a new unblinded sample size re-estimation strategy. The new total 
sample size is calculated from our exact power function for the one stage using the 
estimated variance from the Stage 1 as the true variance. If the sample variance from 
Stage 1 is smaller than the initial variance from the historical data, then we stop at the 
end of Stage 1 and analyze Stage 1 data with the standard t- quantile. Otherwise, we 
collect data from additional subjects. We then analyze the combined data from both 
Stage 1 and Stage 2 with a new test statistic using the pooled variance of two stages. 
The exact critical values for the new test statistics are derived as the largest of u for 
which the following condition holds: the experimentwise type I error rate is exactly 
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Chapter 1  Overview 
Following the 2001 Food and Drug Administration’s Guidance for Industry [1]: 
Statistical Approaches to Establishing Bioequivalence, the Center for Drug 
Evaluation and Research (CDER) recommended that a standard in vivo 
bioequivalence (BE) study design be based on the administration of either single or 
multiple doses of the test (T) and the reference (R) products to healthy subjects on 
separate occasions, with random assignment to the two possible sequences of drug 
product administration. Hence the crossover design for in vivo BE study is the 
primary design studied in regulatory trials. The reference product could be a marketed 
innovator's product previously approved by Food and Drug Administration (FDA) 
and the test product a potential generic substitute manufactured by a different 
pharmaceutical company. The test and reference products could also be different 
formulations, but manufactured by the same pharmaceutical company. 
In a two-period two-treatment crossover design, a group of n1 subjects (Sequence 
1) receives the reference drug, and a profile of the drug concentration within blood 
plasma over time is obtained for each subject. After a washout period to remove any 
carryover effect, this group receives the test drug, and drug plasma concentration-
time profile for each subject is again obtained. A second group of n2 subjects 
(Sequence 2) receives the drugs in the reverse order. Therefore AUC (area under the 
concentration-time curve), Cmax (maximum concentration), and Tmax (time to reach 
the maximum concentration) are obtained from the correspondingly observed 
concentration time profile for each subject under each treatment in each sequence. In 




For the bioequivalence evaluation of pharmacokinetic crossover studies, univariate 
response variables such as log(AUC) and log(Cmax) are often assumed to follow a 
normal distribution in literature and in practice [2, 3]. The investigation by Lacey et 
al. [4] showed the underlying distributions of AUC and Cmax of four different Glaxo 
Wellcome compounds with the number of subjects varying from 29 to 69 are better 
approximated by log-normality rather than normality using p-values of the Shapiro-
Wilk test [5]. Liu and Weng [6] briefly discussed the theoretical distributions of AUC 
and Cmax under joint multivariate normal and multivariate log-normal assumptions 
of the observed plasma concentrations. The FDA Guidance published in 1992: 
Statistical procedures for bioequivalence studies using a standard two-treatment 
crossover design [7] and others [8, 9] provided the rationale for normality of 
log(AUC) and log(Cmax) as follows. Assuming that elimination of the drug follows 
first order and only occurs from the central compartment, the following equation 







==∞−0 , where F 
is the fraction absorbed, D is the administered dose, FD is the amount of drug 
absorbed, and CL is the clearance of a given subject which is the product of the 
apparent volume of distribution ( aV ) and the elimination rate constant (Ke). The use 
of AUC as a measure of the amount of drug absorbed thus involves a multiplicative 
term (CL) which might be regarded as a function of the subject. For this reason, 
Westlake [8, 9] contends that the subject effect is not additive if the data is analyzed 




Logarithmic transformation of the AUC data brings the CL ( ea KV ) term into the 
equation in an additive fashion: 
KeVDFAUC a lnlnlnlnln 0 −−+=∞− . 
Clearly, the above argument is vague and lacks concrete scientific evidence. Thus, 
there is a need to have a systematic investigation of this assumption by simulations of 
individual pharmacokinetic profiles. 
In Chapter 2, we investigate the assumption of normality of the response variables, 
log(AUC), log(Cmax), and log(Tmax) by simulating a large number of concentration 
time profiles from two-stage one–compartment pharmacokinetic models for a wide 
range of parameter choices and measurement error structures. Then the distributions 
of log(AUC), log(Cmax), and log(Tmax) can be investigated by examining the 
departure of the histograms of the standardized response variables from normality for 
large sample studies (e.g., 100,000 subjects) and examining the rejection rates of the 
Shapiro-Wilk normality test for the response variables at a 0.05 significance level for 
small sample size (e.g., 40 subjects) studies.  
In Chapter 3, we present the linear mixed effect model for a two-period two-
treatment cross-over bioequivalence study. Assuming the response variable 
(log(AUC) or log(Cmax)) is normally distributed, we give a brief introduction of test 
statistics for the two one-sided hypothesis tests most commonly used in 
bioequivalence studies and present the power function for the test based on two one-
sided test statistics. We also take a quick look at the power approach. In practice, the 




α (e.g., 0.05) and a lack of significance is often used to incorrectly infer equivalence.  
We derive the power function for the power approach. The two one-sided tests 
procedure is selected because it is recommended by FDA guidance and the two one-
sided tests procedure is superior to the power approach as a test of the hypothesis H0 
below based on Shuirmann’s comparison [10] of the two one-sided tests procedure, 
and the power approach for assessing the equivalence of average bioavailability in 
terms of rejection regions under the assumption that the response variable (log(AUC) 
or log(Cmax)) is normally distributed. 
Denote the population mean bioavailability (log(AUC) or log(Cmax)) of the test 
product by Tµ and the population mean bioavailability of the reference product by Rµ . 
In order to conclude the bioequivalence of the test product and the reference product, 














    . 
Here θ1 and θ2 are pre-specified constants, also called equivalence margins, and 
θ1< θ2.  
The null hypothesis, H0, states that μT and μR are not equivalent. The alternative 
hypothesis, Ha, states that they are equivalent. Ha  is the intersection of the two one-
sided parameter regions, {
RT µµθ −<1 } and { 2θµµ <− RT }. The statistical 
hypotheses H0 and H1 given above are referred to as the “interval hypotheses” in 




In Chapter 4, we present the background, notation and standard assumptions in 
two-period two-sequence crossover designs for tests of bioequivalence and briefly 
derive the joint density function of test statistics and the exact formula for the power 
of the two one-sided tests procedure for testing bioequivalence based on a univariate 
normally distributed response variable. Our derivation for the exact power under 
general parameters only serves for completeness and for expository purposes since 
the explicit power formula under the equal variance for the test and reference 
products and balanced design was published before. However, by allowing for 
unequal variances, it might allow the user to assess the robustness of the power and 
sample size determinations when this assumption is violated. Modest differences in 
variability may not cause concern when the bioequivalence question is being 
addressed. We compare the simulated values with the numerical values and indicate 
how numerical integration easily provides accurate numerical values for power and 
sample size. Then, we compare the numerical results of the exact method with other 
methods including some approximate ones that have been proposed because of ease 
of calculation. 
When planning a bioequivalence study, one needs to specify a true mean 
difference between test and reference for the response variable of interest, along with 
the variance of these responses for both test and reference formulations. This may 
come from a limited pilot study or by looking at data from the reference formulation 
to make an intelligent guess. Because these initial values may be off, providing an 




type I error can improve the chances of success. We henceforth refer to our new 
method as a two stage design for bioequivalence.   
In Chapter 5, we propose a new unblinded sample size re-estimation strategy 
which re-estimates the new total sample size from the exact power function in 
Chapter 4 for the single stage with the replacement of the true variance by the 
estimated variance from the Stage 1. If the sample variance from the first stage is 
smaller than the initial variance from the historical data, then we stop at the end of the 
first stage, and we analyze the first stage data with the standard t quantile. Otherwise, 
we proceed collecting the data from additional subjects and then analyze the 
combined data from both Stage 1 and Stage 2. In order to analyze the combined data 
from Stage 1 and Stage 2, we propose new test statistics using the pooled variance of 
two stages. We search for exact critical values for the new test statistics subject to the 
following constraint: the maximum of the probability of rejecting the non-equivalent 
under the non-equivalent for the two-stage study plus the probability of rejecting the 
non-equivalent under the non-equivalent for the one-stage study in the whole range of 
variance is less than or equal to the nominal level α . With this exact critical value, 
the experiment-wise type I error rate for the sample size re-estimation procedure is 
not inflated.  
Throughout Chapter 3 to Chapter 5, we assume the normality of the response 
variable. In Chapter 6, we consider the impact of the non-normality of the response 
variable on the sample size, power, and type I error rate for the single stage study 




study planning. In Chapter 7, we provide our final conclusions and recommendations 








In a typical pharmacokinetic bioequivalence study with a single dose 
administration, one of the drug products is a reference formulation and the other a test 
formulation. Each subject is administered both formulations in a randomized two-
period crossover design [3]. A concentration-time profile is determined for each 
subject given each formulation. Each single concentration-time profile can be 
modeled by a pharmacokinetic compartmental model [13]. Many software programs 
exist for estimating the pharmacokinetic parameters such as the absorption rate, the 
volume of distribution, etc. [14]. Then, AUC, Cmax, and Tmax can be obtained from 
the fitted pharmacokinetic model. In spite of these elaborate pharmacokinetic models, 
the AUC, Cmax, and Tmax are obtained from the nonparametric method [1] for 
bioequivalence assessment.  
In practice, the univariate response variables such as log(AUC) and log(Cmax) are 
often assumed to follow a normal distribution without much experimental data 
support. For instance, an investigation of observed pharmacokinetic studies in [4] was 
based on numbers of subjects from 29 to 69 and so the power of the Shapiro-Wilk test 
to detect departures from either distribution (lognormal or normal) may have been 
limited.  
In this chapter, we investigate the normality assumption of log(AUC) or log(Cmax) 




concentration profiles over time. In particular, if data is generated using the simplest 
pharmacokinetic models (namely one and two compartment models), will it 
ultimately lead to deciding which distribution of log(AUC), log(Cmax), or log(Tmax) 
is most plausible? There are many software packages, e.g., NONMEM [14] and many 
programs, e.g., SAS/IML [15] available for pharmacokinetic simulations. The 
SAS/IML program [15] provides an opportunity to use the statistical capabilities of 
the SAS package; NONMEM is a specialized-pharmacokinetic modeling software 
package. We write our own SAS program to simulate the plasma concentration 
profiles for streamlining the derived response variables and incorporating the desired 
variance-covariance structures for errors and pharmacokinetic parameters.  
In this chapter, we will investigate the distributional assumption of the normality 
of response variables (log(AUC), log(Cmax), and log(Tmax)) by simulating a large 
number of concentration-time profiles from two-stage pharmacokinetic models for a 
wide range of variability in pharmacokinetic parameters, a wide range of correlations 
of pharmacokinetic parameter vector, and a wide range of measurement error 
structures.  
In Stage 1, we simulate the mean plasma concentration-time profile of each subject 
from the one-compartment pharmacokinetic model using the pharmacokinetic 
parameters (absorption rate, elimination rate, bioavailability, and volume of 
distribution, etc.) of a particular drug whose values follow the log-normal distribution 
from subject to subject. In Stage 2, the plasma concentration-time profile of each 
subject is the result of the mean plasma concentration-time profile of each subject 




log(AUC), log(Cmax), and log(Tmax) from a simulated study are examined in three 
ways.  
First, we compare the estimated density curve of the standardized response 
variables (log(AUC), log(Cmax), and log(Tmax)) for 400,000 simulated subjects with 
the standard normal density curve. We compare the percentiles of the sample 
distribution to those of the standard normal distribution for one case.  
Second, we examine the normality departures of the histogram of the standardized 
response variable for 100,000 simulated subjects for several combinations of 
variability in pharmacokinetic parameters, correlations of pharmacokinetic 
parameters’ vector, and measurement error structures so that the most severe 
normality departure can be spotted. From practical experience, correlation 
coefficients among pharmacokinetic parameters ranging from 0.1 to 0.5 seem 
reasonable. The coefficient of variation (CV) for measurement errors of 0.2 is small 
compared to 0.4 (a highly variable drug has CV>0.3). Coefficient of –log(0.5) is high 
since measurement errors are most commonly assumed to be independent for each 
subject in the pharmacokinetic modeling (see Chapter 3 in NONMEM users guide 
[14]).  
Third, we compare the rejection rates of the Shapiro-Wilk normality test of these 
variables at 0.05 significance level for small sample size (e.g., 40 subjects) studies for 
some choice of parameters. Through the examination of a large sample size study, we 
can obtain a sampling distribution that is very close to the true distribution for the 
response variable and determine how the distribution of the response variable departs 




normality from the rejection rate of the Shapiro-Wilk normality test for the response 
variable based on the small sample size study.. If the rejection rate is much larger 
than the nominal significance level, then the sampling distribution departs from 
normality. However, we would not know the nature of the departure. In addition, the 
normality testing for a small sample (e.g., 40 subjects) has very low power to reject 
the null hypothesis of normality. Hence the rejection rate is not a sensitive method. 
Sensitivity analyses investigate how the sampling distribution of the standardized 
log(AUC) (or the standardized log(Cmax)) for a large number of simulated subjects 
deviates from normality if residual error is distributed as t (a heavy tail distribution),  
the mixture of two normal variables (two subgroups responding differently), or if the 
concentration-time profiles follow a two-compartment pharmacokinetic model with 
normal residual errors. 
In Section 2.2, the two-stage one-compartment pharmacokinetic models are 
described in detail. In Section 2.3, we present the simulation scheme for the 
concentration profiles from a one–compartment pharmacokinetic model with first 
order absorption and first order elimination for many subjects who receive a single 1 
mg oral dose of Ropinirole for treatment of Parkinson’s disease. The simulation is 
motivated by the real example and the estimated means for parameters from the 
reference [16] are used as their true means in the simulation. Subsequently, the 
sampling distributions of log(AUC), log(Cmax), and log(Tmax) are obtained. In 
Section 2.4, we review univariate normality tests extensively and recommend that the 
Shapiro-Wilk test be used for sample sizes less than 2000. In Section 2.5, we closely 




simulated subjects for one case. We also examine the departure from normality of the 
histogram of the standardized response variable for 100,000 subjects simulated from 
one of several combinations of the variances and correlations of pharmacokinetic 
parameters’ vector and measurement error structures. In Section 2.6.1, sensitivity 
analyses illustrate how the distribution of the standardized log(AUC) (or the 
standardized log(Cmax)) for a large number of simulated subjects deviates from 
normality if eij is distributed as t with 5 to 20 degrees of freedom. In Section 2.6.2, 
sensitivity analyses study the validity of the normality assumptions of log(AUC), 
log(Cmax), and log(Tmax) if there is a subgroup with a slower absorption process. In 
Section 2.6.3, we present sensitivity analyses of the effect of different 
pharmacokinetic compartment models on the validity of the normality assumptions of 
log(AUC), log(Cmax), and log(Tmax) from two-compartment model under different 
combinations of the variations of the pharmacokinetic parameters and the variations 
of the measurement errors. In Section 2.7, distributions of log(AUC), log(Cmax), and 
log(Tmax) are examined for a real case with 39 subjects. 
2.2 Pharmacokinetic models and assumed distribution 
Assume that a typical person takes one tablet with dose D orally and the plasma 
concentration-time curve obtained after oral administration of one tablet can be 
described by a one-compartment model with the first-order absorption and 
elimination.  
Let X be the true amount of drug in the body at time t after oral administration of 
one tablet with dose D. Let Xa be the true amount of drug at the absorption site at time 




an apparent first-order absorption process, is eliminated by a first-order process, and 
distributes in the body according to a one-compartment model, the change in the 








dX −= .                                                                            (2.2) 
Here ka is the apparent first-order absorption rate constant and ke is the apparent 
first-order elimination rate constant for the drug. Note that when t=0, X=0 and 
Xa=FD. Now we turn to solving the differential equations (2.1) and (2.2), we obtain 









Assuming the apparent volume of a typical person is aV  and bioavailability 
fraction is F, we obtain the relationship between the true concentration of drug (
tC
µ ) 











Let Cij denote the jth measurement of plasma concentration for j=1,2,…, ni; also 







plasma concentrations are obtained. Suppose that the relationship between 
the mean of Cij and tij for a given subject i is a nonlinear function f(tij, βi), where βi is 
a ( 1×p ) vector of pharmacokinetic parameters for the ith subject which can vary 




that the form of f is common to all subjects, while βi differs for each subject i. This 
may be written as ),()|( ii ββ ijCij tfCE ij == µ . Note that f(tij, βi) is often assumed to be 
a nonlinear function of tij, and βi is assumed to be in the form of a summation of 
exponential functions. It is common to represent the body as a system of 
compartments and to assume that the rates of transfer between compartments follow 
first-order or linear kinetics when we characterize the concentration of a drug in the 









which is derived from the one-compartment linear pharmacokinetic model for plasma 
concentration after a single oral dose, D, where βi= )),1/(,,( , ′− iaiiii VFFkeka ,  
10 , ≤≤> iii Fkeka .  
Now we can define the following two-stage models: 
Stage 1 (between subject variability) 
Variation among subjects is accounted for through the subject-specific regression 
parameters (βi). Parameters may differ due to unexplained variation from the natural 
biological or physical variability among subjects or the run-to-run variation in assay 
procedures.  
In general, subjects in pharmacokinetic bioequivalence studies are chosen from a 
relatively homogeneous population of healthy volunteers. Thus, variation among 
pharmacokinetic parameters across subjects is often attributable mainly to random 
variation among subjects rather than to differences in individual demographic and 
physiological characteristics that would be more pronounced in a heterogeneous 




In bioequivalence studies, it is appropriate to assume that inter-subject variation is 
due to unexplained noise: 
( )iβogl = ( )γlog ib+ .                                                                                        (2.3) 
In Model (2.3), ( )iβogl  is the vector of logarithms of the components of the vector 
iβ , γ  is a positive vector of population pharmacokinetic parameters, ( )γlog is the 
vector of logarithms of the components of the vector γ ,  and the error vector bi is the 
normal random component of inter-subject variation, which might be taken to have 
mean vector zero and covariance matrix Σ. In practice, pharmacologists often assume 
( )iβogl  is distributed as a normal random variable [14, 16-18]. This assumption is 
based on physiological and biological reasons such as positively skewed iβ  [17]. On 
the contrary, this assumption has not been validated. However, in one type of  
bimodal population, a small percentage of the population has a slower absorption 
process. This two-subpopulation case corresponds to a two-component mixture of the 
multivariate-normal ( )iβogl  distribution where two components differ only by 
log( ka ). 
Stage 2 (Within subject variability) 
Assume that for Subject i, the jth concentration follows the model 
ijijijij etgCy +== ),()log( iβ  .                                                                        (2.4) 
Here eij is a normal random measurement error with 0)|( =iβijeE and 




Let ],...,[ 1 ′= iini yyiy  be the log-transformed concentrations of the i
th subject and 
furthermore let ],...,[ 1 ′= iini eeie  be the errors of the i
th subject. Let ( )iig β  be the 
vector of concentration functions of the ith subject. 
 ( ) ( ) ( ) ( )[ ]′= iiiii ββββg ,...,, 21 iinii tgtgtg .                                         (2.5) 
We can summarize the data for the ith subject as iii egy += )( iβ , where we 
assume 0)|( =iβieE , ii Rβ =)|( ieVar , and iR  is the variance-covariance matrix of 
log-transformed data within the ith subject. 
Let ( )ijiij tXe = , where ( ){ }0, ≥ttX i  is all Ornstein-Uhlenbeck process [19] 
defined by the following stochastic differential equation:  
( ) ( ) ( )tdWdttXtdX ii σξ +−= , ( ) ( )2,0~0 σNX i , and 0≥t .  Here 0>ξ  and 0>σ  
are unknown parameters, and ( )tW  is the standard unit Wiener process. The solution 
to the preceding differential equation is ( ) ( ) ( ) ( )( ) s
t
ii dWstXttX ∫ −−+−=
0
exp0exp ξσξ . 
Thus we have 11 ii ue = , ( )( ) 1,11, exp +++ +−−= jiijjjji uette ξ , mj ,..,2,1= , where 
imi uu ,...,1  are independent distributed normal variables with 0)|( =iβijuE , 
( ) 21 | σ=iβiuVar , and ( )( )( )ξσ jjij ttuVar −−−= +12 2exp1)|( iβ . Hence 
( )( ) jktteeCov jkikij >−−= ,2exp)|,( 2 ξσiβ . If CV denotes the coefficient of variation 
of the untransformed concentration data, then the variance of the log-transformed 
concentration is computed as σ2=log(1+CV2). 
We assume that bi is independent of eij. A supposition of normality of bi and eij in 




and hence some sensitivity analyses of bioavailability parameters (log(AUC) and 
log(Cmax)) to these distributions are essential. 
2.3 Simulation scheme 
 
Motivated by a real world example, we will simulate the concentration profiles 
from Models (2.3) to (2.5).  Assuming the estimate means are the true value, this is a 
one–compartment pharmacokinetic model with the first order absorption and first 
order elimination for many subjects to whom are administered a single 1 mg oral dose 
of Ropinirole for treatment of Parkinson’s disease. This drug is a novel non-ergoline 
dopamine D2 receptor agonist, for which Kaye and Nicholls [20] summarized clinical 
pharmacokinetics. We obtain the estimated means of untransformed pharmacokinetic 
parameters (ka, ke, F, and aV ) from [20]. Here, ka is the absorption rate in hr
-1; ke is 
the elimination rate in hr-1; F is the bioavailability fraction, 0≤F≤1; and aV  is the 
apparent volume in liters (L). In the reference [20], F is reported to be approximately 
0.5, aV  at steady state is approximately 7.2 L/kg after oral administration, Tmax  
approximately lies in the range from 0.5 to 4 hours after dosing, and the elimination 





693.0=  (the well-known approximate relationship [13] between 















max  (the approximate relationship [13], among Tmax, 
absorption rate, ka , and ke ) when we assume Tmax to be 4.21 hours. According to 




in the range from 65 to 75 kg.  The average weight of a patient is assumed 70 Kg, and 
so the average of aV  is 525 Liters. 
The following detailed steps delineate how to simulate the plasma concentration 
profiles: 
1) The coefficients of variation for person-level untransformed pharmacokinetic 


































2) Assume that the log-transformed vector of pharmacokinetic parameters for the ith 
subject follow a multivariate normal distribution and write this as log of vector 
entries: ),( ~,
1




















. For a log-normal ( λ , 2σ ) variable, 
the coefficient of variation squared 2pkcv  (variance divided by the square of mean) is 
1
2
−σe and 21 pkcv+=σ . The correlation matrix of these log-transformed 
pharmacokinetic parameters is assumed to be R .  We further assume each parameter 
on this scale is equally correlated. Here we need to convert the marginal mean 
( {1,2,3,4}j ],[ ∈∀jη ) and coefficient of variation (cvpk[j], {1,2,3,4}j ∈∀ ) for each 
untransformed pharmacokinetic parameter obtained from the reference into the 
marginal mean ( {1,2,3,4} ],[ ∈∀jjλ ) of each log-transformed pharmacokinetic 
parameter and variance matrix ( Λ ) of  log-transformed pharmacokinetic parameters 




 {1,2,3,4},j ),])[(1log(*5.0])[log(][ 2 ∈∀+−= jcvjj pkηλ and
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. Therefore, ⋅= MΛ R M⋅ . 
3) Independently generate m subjects’ random vectors of log-transformed 
pharmacokinetic parameters, ( )( )′− iaiiii VFFkeka ,,1,,log , from the distribution in 
Step 2. Then convert this to ( )′iaiii VFkeka ,,,, , for i=1, 2,…, m. 
4) For a given individual i, simulate concentration profile at time points 
t= ( )′36,32,28,24,22,20,18,16,14,12,10,8,6,4,3,2,5.1,1,2/1,4/1 , measured in hours. 
Let ni be the number of sampling times. The choice of the sampling schedule is 
typical for these types of studies and follows the general rule: more frequent 
samplings earlier on after dosing (e.g., sampling every 15 minutes for the first few 
samples and sampling every half hour for the next few samples) and less frequent 
samplings later on (e.g., sampling every 2 or 3 hours after half-life). This flexible 
sampling schedule allows more information for the rapidly changing period prior to 
the half-life. 
Let ijt be the jth sampling time point after dosing for Subject i and let ijC be the 




























for Subject i, since analytical integration from this complicated nonlinear and 
stochastic model is not tractable, this calculation is done in practice. 
6) Obtain Cmaxi= ( )ij
j
CMax  from all observed values for Subject i. 
7) Obtain Tmaxi (time to reach Cmaxi) from all observed values for Subject i. 
8) Perform the Shapiro-Wilk W test (discussed in Section 2.4) for the goodness of fit 
of normal distribution of log(AUCi), log(Cmaxi), and log(Tmaxi), i=1,2,…,m. Small 
sample sizes such as m=40 will be investigated and a large sample size of 400,000 
will also be investigated for the true distribution arising from random-effects 
pharmacokinetic models.  
9) Repeat Steps 2 to 8 for Snum=10,000 times when m=40.  
10) Calculate the rejection rate of the goodness of fit test of log-normality at nominal 











. The 0.05 significance level is chosen 
based on the usual type I error rate of 5% used by the regulatory and industrial 
statisticians for each small bioequivalence study. 
2.4 Univariate normality test 
 
The goodness-of-fit problem is to decide whether or not the random sample (xi, 
i=1,.., n) follows one of a parameterized family ( )θ,xF  of distributions, whereθ may 
be either be specified in advance or estimated. The W statistic proposed by Shapiro 




power of concluding the non-normality which slightly deviates from normality is very 
high when n>2,000 [21]. The test statistic W [5] was defined for a random sample 


















, where ( )ix is the 
thi  order statistic (the 
thi value from the bottom of the list of sample variables in increasing sorted order), 
x is the sample mean, and ia is a constant determined from the expectation and 
variance of the thi order statistic of a sample of n standard normal observations, 
i=1,2,…, n. W must be greater than zero and less than or equal to one. Small values of 
W lead to the rejection of the null hypothesis of normality. The distribution of W is 
highly skewed. When the sample size is greater than three, the coefficients to 
compute the linear combination of the order statistics in Proc Univariate, a SAS 
procedure [22], are approximated with an approximate normalizing transformation 
suitable for computer implementation [23]. According to this method, variable nZ  
defined by ( )( )( ) 000 /1loglog σµγ −−−−= nn WZ  for 4≤n≤11 or 
( )( ) 00 /1log σµ−−= nn WZ for 12≤n≤2000 are treated as precisely normally 
distributed, where 000  and , , σµγ are functions of n from simulation results, and Wn is 
W-statistic value for sample size n. Royston [23] extended the Shapiro-Wilk W test up 
to sample size 2000. Large values of nZ indicate departure from normality. When the 
sample size is larger than 2000, other goodness of fit tests such as the chi-squared test 
or tests based on the empirical distribution function such as the original or modified 
Kolmogorov-Smirnov test, Cramer-von Mises or Anderson-Darling tests are used. 
The main purpose of the chi-squared test is to provide a quantitative test of the 




hypothesis is: the observations are randomly drawn from a specified theoretical 
distribution. The chi-squared test can be used with either continuous or discrete 
distribution. Under the null, the chi-squared test follows the chi-squared distribution 
in large samples with the degrees of freedom equal to the number of cells minus 1 
minus the dimension of the estimated parameter θ  [24, 25]. 
Another class of goodness-of-fit statistics is empirical distribution function (EDF) 
statistics because they are based on a comparison of ( )xF  with the empirical 
distribution function ( )xFn . Kolmogorov-Smirnov, Cramer-Von Mises, and 
Anderson-Darling test are examples of EDF statistics tests.  
If ( )xF  is continuous and completely specified, EDF statistics is more powerful 
than the chi-squared test. The Kolmogorov-Smirnov statistic is the largest vertical 
distance between the fully specified cumulative distribution function ( ( )xF ) and the 
EDF ( ( )xFn ), which is a step function that takes a step of height 1/n at each 
observation. This test only applies to continuous distributions and tends to be more 
sensitive near the center of the distribution than at the tails. Anderson-Darling test 
[26] uses the quadratic class EDF, which is based on the weighted and integrated 
squared difference ( ( )xFn - ( )xF )2. This test gives more weight to the tails than the 
Kolmogorov-Smirnov test does by setting a function weighting the square difference.  
Similarly, Cramer-von Mises test [27] is also based on the quadratic class of EDF 
statistics, but the weight function is set to 1. The Cramer-von Mises test and the 
Anderson-Darling test better takes into account the variation in the whole data; while 




If ( )xF  is not completely specified, the mean and/or the variance have to be 
estimated from the data. In such cases, the critical threshold for any of the three EDF 
statistics is no longer valid. However, some work [28-30] has made it possible to use 
EDF statistics for two very important practical situations in which the distribution 
tested is normal or exponential, with parameters to be estimated. For a large sample 
size (n>2000), the Kolmogorov-Smirnov test, Cramer-von Mises test, and Anderson-
Darling test are usable for normal and exponential distributions when the mean and 
variance are estimated from the data after the percent points are obtained from 
simulations [30]. Once the EDF test statistics (Kolmogorov-Smirnov test, Cramer-
von Mises test and Anderson-Darling test) are computed, then the associated p-values 
are calculated. SAS procedure: PROC UNIVARIATE [22] uses internal tables of 
probability levels that are similar to those given by D'Agostino and Stephens [31]. 
For continuous, asymmetric and long-tailed distributions (e.g., ( )12χ , ( )22χ , 
( )42χ , and  ( )102χ ) and continuous, asymmetric, and short-tailed distributions (e.g., 
( )1,2Beta  and ( )2,3Beta ),  the W statistic is most sensitive and the Kolmogorov-
Smirnov test and Cramer-von Mises test show, in general, relatively poor sensitivity 
for these alternative [21]. For continuous, symmetric, and long-tailed distributions 
(e.g., ( )1Cauch , ( )2Cauch , and ( )4Cauch ) and continuous, symmetric, and short-
tailed distributions (e.g., ( )1,1Beta  and ( )2,2Beta ), the W statistic outperforms the 
Kolmogorov-Smirnov test and Cramer-von Mises test [27]. Hence the Anderson-
Darling test implemented by SAS PROC UNIVARIATE is chosen in this chapter for 




UNIVARIATE’s W test extended by Royston is chosen for assessing the log-
normality of the response variable when n<2000. 
2.5 Distributions of log(AUC), log(Cmax), and log(Tmax) 
2.5.1 One case study 
 
To illustrate the simulated plasma concentration-profiles and distributions of the 
response variables, we will simulate plasma concentration-time profiles using the 
simulation scheme in Section 2.3 for one particular set of parameters, that is , a one-
compartment model with CV=0.2, ξ =-log(0.5), )'3.0,3.0,3.0,3.0(,5.00 == pkcvρ , and 
( )( )′− iaiiii VFFkeka ,,1,, = (1.5,0.12,1,525)’. Figure 2.1 shows concentration-time 
profiles for a sample of 20 subjects simulated under the models (2.3)-(2.5).  
Throughout this chapter, the log(AUC), log(Cmax), and  log(Tmax) are each 
standardized through centering by its sample mean and scaling by its sample standard 
deviation. The density curve of the standardized log(AUC) or log(Cmax) is estimated 
by the normal kernel density estimation method with bandwidth which is 0.9 times 
the minimum of the standard deviation and the interquartile range divided by 1.34 
times the sample size to the negative one-fifth power [32].  
Figure 2.2 shows that the estimated density curve of the standardized log(AUC) for 
400,000 simulated subjects is very close to the standard normal density. According to 
Table 2.1, the estimated quantiles for the standardized log(AUC) are generally not far 
away from the standard normal percentiles, but for example the 1% and 2% quantiles 
for standardized log(AUC) differ noticeably from the normal percentiles, showing 




effects in the pharmacokinetic model are normally distributed. The differences are as 
high as 0.2 in the tails, becoming closer (within about 0.05) in the center of the 
distribution.  
Figure 2.3 shows that the estimated density curve of the standardized log(Cmax) is 
skewed to the left compared to the standard normal density. Table 2.1 shows that the 
estimated quantiles for the standardized log(Cmax) are consistently larger than those 
for the standard normal. The differences are as high as 0.3 in the tail. 
Figure 2.4 shows that the cumulative distribution curve of the standardized 
log(Tmax) with a fixed number of discrete points significantly deviates from the 
standard normal cumulative distribution curve. Table 2.1 shows that the 1% tail 
quantile of standardized log(Tmax) is 17% larger than the 1% standard normal 
quantile; and the 99% tail quantile of standardized log(Tmax) is 12% larger than the 
99% standard normal quantile. In practice, Tmax is assessed subjectively and is not 
assessed by equivalence criteria.  
Figure 2.1 An example of concentration-time profiles from 20 subjects simulated from one-
compartment model with CV=0.2, ξ =-log(0.5), ( )'3.0,3.0,3.0,3.0,5.00 == pkcvρ , and 





Figure 2.2 Comparison of the standard normal density and the estimated density curve of log(AUC) 
from 400,000 subjects simulated from one-compartment model with CV=0.2, ξ=-log(0.5), 
( )'3.0,3.0,3.0,3.0,5.00 == pkcvρ and ( )( ) ( )′=′− 525,1,12.0,5.1,1,, ,,, iaiiieia VFFkk . 
 
 
Figure 2.3 Comparison of the standard normal density and the estimated density curve of log(Cmax) 
from 400,000 subjects simulated from one-compartment model with CV=0.2, ξ =-log(0.5), 











Figure 2.4 Comparison of standard normal distribution function and cumulative 
distribution function of log(Tmax) from 400,000 subjects simulated from a one-
compartment model with CV=0.2, ξ=-log(0.5), ( )'3.0,3.0,3.0,3.0,5.00 == pkcvρ and 




Table 2.1 Comparison of observed extreme quantiles for standardized log(AUC), log(Cmax), and 
log(Tmax)  with standard normal extreme quantiles for 400,000 subjects simulated from one-
compartment model with CV=0.2 , ξ=-log(0.5), ( )'3.0,3.0,3.0,3.0,5.00 == pkcvρ , and 
( )( ) ( )′=′− 525,1,12.0,5.1,1,, ,,, iaiiieia VFFkk  







0.10% -3.338 -2.694 -2.910 -3.090 
0.50% -2.749 -2.258 -2.910 -2.576 
1% -2.451 -2.043 -1.920 -2.326 
2% -2.142 -1.816 -1.920 -2.054 
5% -1.692 -1.475 -1.920 -1.645 
95% 1.595 1.771 1.628 1.645 
97.50% 1.882 2.264 1.628 1.960 
99% 2.204 2.908 2.039 2.326 
99.50% 2.423 3.359 2.039 2.576 
99.90% 2.883 4.335 2.357 3.090 
 
2.5.2 Examination of distributions of response variables for 8 scenarios 
 
We compare the distributions of the standardized log(AUC), log(Cmax), and 




obtain the rejection rate of the normality testing for 2500 trials, each of which has 40 
subjects. Note that testing normality for a small sample (e.g., 40 subjects) has very 
low power to reject the null hypothesis of normality.  
From Table 2.2, it can be seen that 1) the median of the standardized log(AUC) is 
off 0 by less than 0.1 for all cases; 2) the 75th percentile is about 0.15 larger than the 
75th standard normal quantile for Cases 1 to 4 and about 0.15 smaller for Cases 5 to 8, 
and 3) the 25th percentile is  0.07 smaller than the 25th standard normal quantile for 
Cases 1 to 4 and about 0.08 larger for Cases 5 to 8. Figure 2.5 shows that the 
histogram (300 breaks) of the standardized log(AUC) has heavy tails compared to the 
density of N(0,1) for all 8 cases. 
The rejection rates of the Shapiro-Wilk normality test of log(AUC) at 0.05 
significance level are about 5% for Cases 3, 5, 6, 7, and 8. The rejection rates of the 
Shapiro-Wilk normality test of log(AUC) at 0.05 significance level are approximately 
6.5% for Cases 1, 2, and 6.  
From Table 2.2, it can be seen that 1) the mean of the standardized log(Cmax) is 
less than 0 by 0.15 for Cases 1, 3, 5, and 7; 2) the 75th percentile is about 0.1 larger 
than the 75th standard normal quantile for Cases 1 and 3; the same holds for Cases 5 
and 7, and about 0.3 smaller for Cases 2, 4, 6, and 8; and 3) the 25th percentile is  0.2 
to 0.3 larger than the 25th standard normal quantile for Cases 1, 3, 5, and 7 and about 
0.2 smaller for Cases 2, 4, 6, and 8. Figure 2.6 shows that the histogram (300 breaks) 
of the standardized log(Cmax) is skewed to the right of N(0,1) if 0=ξ  or to the left if 




log(Cmax) at 0.05 significance level for Cases 1, 3, 5, 6, 7, and 8 are less than 7.5% 
and for Cases 2 and 4 are greater than 23%. 
Figure 2.7 shows that the CDF of the standardized log(Tmax) has the fixed number 
of mass points and is above the standard normal CDF for all cases. The rejection rates 
of the Shapiro-Wilk normality test of log(Tmax) at 0.05 significance level for almost 
all cases are larger than 50%. 
 
Table 2.2 Description of cases with simulated 100,000 subjects from Models 2.1 to 2.5 where PK 
parameters with ( )[ ] [ ] [ ]1,1,1,1 ,525,1,12.0,5.1,1,, pka cvVFFkekaE =′=′−= cvη , and 
],...,[ 1 ′= iini eeie . 
Case  ηlog  
~ ),( ΛλN  
Residual 
error eij 
Quantiles for N(0,1): (25th, 50th, 75th)=(-0.674,0,0.674) 
Quantiles of the standardized 
log(AUC)  
Quantiles of the standardized 
log(Cmax) 
0ρ  pkcv  ξ  CV 25
th  50th 75th 25th  50th 75th 
1 0.5 0.3 0 0.4 -0.749 0.022 0.780 -0.413 0.152 0.737 












3 0.1 0.3 0 0.4 -0.766 0.009 0.773 -0.490 0.148 0.804 
4 0.1 0.3 0.5 0.2 -0.715 0.075 0.852 -0.973 -0.253 0.539 
5 0.5 0.2 0 0.4 -0.590 -0.052 0.478 -0.337 0.136 0.625 
6 0.5 0.2 0.5 0.2 -0.551 0.017 0.576 -0.865 -0.294 0.382 
7 0.1 0.2 0 0.4 -0.597 -0.050 0.483 -0.378 0.134 0.673 




















































2.6 Sensitivity analyses  
 
In Section 2.5, the examination of distributions of 9 cases with large samples 
shows some deviations of log(AUC) from normality. The 25th and 75th percentiles of 
log(AUC) are slightly different from the 25th and 75th percentiles for the standard 
normal distribution, respectively. The 50th percentile of log(AUC) is close to 0. It also 
shows that log(Cmax) distributes skewed to the right or the left. The 25th, 50th, and 
75th percentiles of log(Cmax) are all different from the 25th, 50th, and 75th percentiles 
for the standard normal distribution, respectively. But the rejection rate of the 
Shapiro-Wilk normality test of log(Cmax) is slightly higher than 5% percent, but less 
than 7.5% for all cases. Clearly, the Shapiro-Wilk normality test of log(AUC) with 
small samples for all cases has very low power to reject the null hypothesis of 
normality. 
Since simulations in Section 2.5 are based on one-compartment pharmacokinetic 
models with normal measurement errors, we will demonstrate whether or not 
log(AUC) and log(Cmax) can be reasonably assumed as random normal variables by 
simulations if data come from the one-compartment pharmacokinetic models with 
symmetrical measurement errors distributed as t and with a bimodal population 
corresponding to one subgroup having a slower absorption process. We will also 
demonstrate whether or not log(AUC)  and log(Cmax) can be reasonably assumed to 
be normally distributed by simulations if data come from two-compartment 





2.6.1 Symmetrical measurement errors distributed as t 
 
We investigate how the distribution of the standardized log(AUC) (or the 
standardized log(Cmax)) for large samples of simulated subjects deviates from 
normality if eij is distributed as a ( )νt  with =ν  5, 10, 15, or 20. We compare the 
histogram of the empirical standardized log(AUC) (or the standardized log(Cmax)) 
with the standard normal density curve. For the standardized log(Tmax), we compare 
the cumulative distribution function (CDF) of the standardized log(Tmax)) with the 
normal CDF.  
For Cases 1 to 8 in Table 2.3, we assume that imi ee ,...,1 are independent and 
identically distributed t-variables for each i by letting 0=ξ , and we also vary the ν  
values from 5 to 20 by 5 and CV values from 0.2 to 0.4 by 0.2 but fix the 
pharmacokinetic parameters’ CVs and correlation at )'3.0,3.0,3.0,3.0(=pkcv  and 
5.00 =ρ , respectively. For Cases 9 to 12, imi ee ,...,1 are the correlated t-variables for 
each i by letting )5.0log(−=ξ . 
Figure 2.8 shows that the histogram of the standardized log(AUC) for 100,000 
simulated subjects is very close to the standard normal density curve for all cases 
except Cases 1 and 9 (ν =5 and CV=0.4) in which the histograms are slightly skewed 
to the right of the standard normal density curve. Table 2.3 shows that the 25th, 50th, 
and 75th percentiles of log(AUC) are all very close to the 25th, 50th, and 75th 
percentiles for the standard normal distribution, respectively. The rejection rate of the 
Shapiro-Wilk normality test at 0.05 significance level for log(AUC) is about 5% if 




Figure 2.9 shows that the histogram of the standardized log(Cmax) is skewed to 
the right compared to the standard normal density whenν ≥5 and CV= 0.4, and the 
histogram of the standardized log(Cmax) has a sharper peak and skew to the left 
compared to the standard normal density whenν ≥5 and CV= 0.2. The 25th, 50th, and 
75th percentiles of log(Cmax) are all different from the 25th, 50th, and 75th percentiles 
for the standard normal distribution, respectively. The rejection rate of the Shapiro-
Wilk normality test at 0.05 significance level for log(Cmax) is about 5% whenν ≥10 
except Case 3 (8.1%) and above 10% whenν =5.  
Figure 2.10 shows that the CDF of the standardized log(Tmax) has the fixed 
number of mass points and is above the standard normal CDF for all cases.  
In conclusion, the normality assumption of log(AUC) seems reasonable if the 
independent and identical measurement errors are assumed to be ( )10t , moderately 
heavy tails. The normality assumption of log(Cmax) is skewed even if the 
independent and identical measurement errors are assumed to follow t distribution. 


















Table 2.3  Description of cases with 100,000 simulated subjects from Models 2.1 to 2.5 where PK 
parameters with ( )[ ] [ ]  525,1,12.0,5.1,1,, ′=′−= aVFFkekaEη , and ],...,[ 1 ′= iini eeie , with 
)'3.0,3.0,3.0,3.0(=pkcv  and 5.00 =ρ . 
Case  Error eij~ ( )νt  Quantiles for N(0,1): (25th, 50th, 75th)=(-0.674,0,0.674) 
  Standardized log(AUC) Standardized log(Cmax) 






5 0.4 -0.626 0.081 0.774 -0.366 0.353 1.160 
2 5 0.2 -0.651 0.025 0.677 -0.768 -0.226 0.343 
3 10 0.4 -0.669 0.020 0.694 -0.460 0.197 0.892 
4 10 0.2 -0.668 -0.001 0.656 -0.815 -0.298 0.232 
5 15 0.4 -0.675 0.013 0.681 -0.491 0.153 0.823 
6 15 0.2 -0.672 0.001 0.653 -0.829 -0.317 0.211 
7 20 0.4 -0.691 0.003 0.669 -0.506 0.133 0.793 




5 0.4 -0.645 0.070 0.763 -0.514 0.123 0.837 
10 5 0.2 -0.622 0.040 0.682 -0.698 -0.171 0.435 
11 10 0.4 -0.669 0.015 0.676 -0.565 0.020 0.666 
























































2.6.2 Mixed population: one subgroup with a slower absorption process 
 
We assume in this subsection that the population of subjects consists of two 
subgroups. One subgroup has a slower absorption process. This could happen if 
coating on the pill took longer to digest for some people. To illustrate how the 
distribution of the standardized log(AUC) or the standardized log(Cmax) for large 
samples of simulated subjects deviates from normality, given that there is a subgroup 
with a slower absorption rate, we will compare the histogram of the standardized 
log(AUC) or the standardized log(Cmax) to the standard normal density curve. In this 
subsection we simulate the pharmacokinetic plasma-concentration profiles from two 
subpopulations: 70% of population has the mean ka=1.5 hr-1 and the rest of 




and identically distributed normal variables for each i by letting 0=ξ , CV =0.2, and 
the pharmacokinetic parameters’ cv values and correlation at )'2.0,2.0,2.0,2.0(=pkcv , 
and 3.00 =ρ . 
The left graph in Figure 2.11 shows that the histogram of the standardized 
log(AUC) for 100,000 simulated subjects is very close to the standard normal density 
curve. The right graph in Figure 2.11 shows that the histogram of the standardized 
log(Cmax) for 100,000 simulated subjects appears to be quite different from a bell 
shaped curve.  
 
Figure 2.11 Comparison of standard normal density and sample histogram of the standardized 
log(AUC)  and log(Cmax) from 100,000 subjects simulated from one-compartment model (1) with 
CV=0.2 , ξ =0, and ( )'2.0,2.0,2.0,2.0,3.00 == pkcvρ for a mixed population: 70% of population 
with the mean vector ( )( ) ( )′=′− 525,1,12.0,5.1,1,, ,,, iaiiieia VFFkk  and 30% of population with 
the mean vector ( )'3.0,3.0,3.0,3.0,5.00 == pkcvρ , and 








2.6.3 Two-compartment pharmacokinetic models with normal measurement errors 
 
To contrast the results of previous simulations with those of analogous simulations 
from a two-compartment pharmacokinetic model, we would ideally consider the two-
compartment model for the same drug Ropinirole for which we simulated the one-
compartment model in Section 2.4. However, the pharmacokinetic parameters for the 
two-compartment model of Ropinirole are not available in the literature. Hence we 
have to switch to a different drug, Digoxin, whose pharmacokinetic parameters for 
the two-compartment pharmacokinetic model were published in [33]. The cardiac 
glycoside Digoxin [33] has a low therapeutic index and serious side-effects. 
In a two-compartment model, Compartment 1 represents the central compartment, 
compartment 2 the "tissue" or peripheral compartment, kaV ,  the apparent volume of 
the kth compartment, and kjk the apparent first-order rate constant for transfer of drug 
from the jth to the kth compartment (k = 0 represents an elimination process). The 
equation in [33] describing the time course of drug concentration in the central 
compartment of this model for the ith subject at time tij after an intravenous bolus 
injection (dose D) is 



















),()|( ii ββ      (2.6),  
where ( ) ( ) 


 −+++++= iiiiiiiii kkkkkkkk 1021
2
102112102112 45.0λ , 
( ) ( ) 


 −++−++= iiiiiiiii kkkkkkkk 1021
2
102112102112 45.0γ , and βi= ),,,( 1102112 ′iiii Vkkk . 
Based on Models 2.3 to 2.5, we will simulate the concentration profiles in the 




average person assumed to weigh 70 kilograms, who receives 1 mg Digoxin by rapid 
bolus injection. 
The following steps will give the details of how to simulate the plasma 
concentration profiles: 
1) Obtain the means of pharmacokinetic parameters ),,,( 1,102112 ′aVkkk  from [33]. In 
[33], the volume of distribution (Va,1) is 53.69 Liters (for an average person 
weighing 70 Kg); k12 is 0.76 hr-1, k21 is 0.12 hr-1, and 10k is 0.29 hr
-1.  
2) Several sets of coefficients of variation of pharmacokinetic parameters are 





































































E cvη  
3) Assume that the vector of pharmacokinetic parameters and transformed 
parameters for the ith subject follows a log-normal distribution, denoted 
as ( ) ),(normal-log ~ ,1,,10,21,12 Λλ′iaiii Vkkk . The correlation matrix of these log-
transformed pharmacokinetic parameters is assumed to be R  without any 
reference.  Here we need to convert the marginal mean ( {1,2,3,4} ],[ ∈jjη ) and 
coefficient of variation (cv[j], {1,2,3,4}∈j ) for each untransformed 
pharmacokinetic parameter obtained from the reference into the marginal mean 
( {1,2,3,4} ],[ ∈jjλ ) of each log-transformed pharmacokinetic parameter and 





 {1,2,3,4}, ),])[(1log(*5.0])[log(][ 2 ∈+−= jjcvjj pkηλ and
4*4





























, it follows that ⋅= MΛ R M⋅ .  
4) For each of m subjects, generate a random vector of pharmacokinetic parameters 
and transformed parameters, ( )′iaiii Vkkk ,1,,10,21,12 ,,, , from the distribution in Step 3. 
Here i=1,2,…,m.  
For a given individual i, simulate concentration profiles ( ijC ) at time points (in 
hours),  
t= ( )′72 ,48 ,24 ,16 ,8 ,6 ,4 ,3 ,2 ,1 ,4/3 ,2/1 ,30/11 ,10/3 ,30/7 ,6/1 ,15/2 ,10/1 ,15/1 ,30/1  
and ni is 20. We assume ni is the same for all subjects. The choice of sampling 
schedule follows [33].  
Let ijt be the jth sampling time point after dosing Subject i and let ijC be the 
concentration at ijt , j=1,2,…,ni. Here, 



















),()|( ii ββ .   











1,5.0  for 
Subject i. 
6) Obtain Cmaxi= ( )ij
j
Cmax  from all observed values for Subject i. 




8) Obtain the goodness of fit of normality of log(AUCi), log(Cmaxi), and log(Tmaxi), 
i=1,2,…,m. 
9) Repeat Steps 2 to 8 for Snum=10,000 times. 














To illustrate how the distribution of the standardized log(AUC) or the standardized 
log(Cmax) deviates from normality if the data is described by a two-compartment 
model, we examine the sampling distribution of the standardized log(AUC) (or the 
standardized log(Cmax)) under various combinations of pharmacokinetic parameters’ 
variation and measurement errors. Since there are more pharmacokinetic parameters 
that vary from subject to subject in the two-compartment model than those in the one-
compartment model, it is even more restrictive than before to assume that their 
across-subject joint distribution is multivariate lognormal. From Table 2.4, we can 
easily see that the 25th, 50th, and 75th quantiles for log(AUC) (or log(Cmax)) simulated 
from the two-compartment model are correspondingly similar to the 25th, 50th, and 
75th quantiles for log(AUC) (or log(Cmax)) simulated from the one-compartment 
model. Hence the sampling distributions of the standardized log(AUC) for all cases in 
Figure 2.11 are similar to the first 8 cases in Figure 2.5 of Section 2.5.2.  The 
sampling distributions of the standardized log(Cmax) for all cases in Figure 2.12 are 
similar to the first 8 cases in Figure 2.6 of Section 2.5.2. It seems that the sampling 




Section 2.5.2 are not greatly affected by the choice of compartment model, but rather 
by the distributions of the pharmacokinetic parameters and distribution of the 
measurement errors.  
Table 2.4 Quantiles of log(AUC) and log(Cmax) at 0.05 significance level (10,000 simulations) for 40 
subjects with [ ]1,1,1,1pkcv=cv and residual errors ],...,[ 1 ′= iini eeie ,ξ =0, and CV=0.4. 
 
Case  ηlog  ~ ),( ΛλN  Quantiles for N(0,1): (25
th, 50th, 75th)=(-0.674,0,0.674) 
the standardized log(AUC)  the standardized log(Cmax) 
0ρ  pkcv  25
th  50th 75th 25th  50th 75th 
1 0.5 0.3 -0.792 0.044 0.875 -0.446 0.317 1.094 
3 0.1 0.3 -0.728 0.011 0.741 -0.419 0.317 1.061 
5 0.5 0.2 -0.616 -0.030 0.549 -0.356 0.248 0.878 



















2.7 One real case  
 
We would like to examine the sampling distributions of AUC, Cmax, and Tmax 
from a pharmacokinetic study of an orally administered agent. 
This was a single-dose, randomized, open-label, two-period, two-sequence, two-
treatment, crossover, comparative bioavailability study of the generic product to the 
innovative product. The products were studied using a crossover design with 40 
normal, healthy volunteers being administered a single oral dose under fasting 
conditions.  There were 39 subjects in the study because one subject withdrew from 
the study. Plasma concentration sampling times are pre-dose and at 0.25, 0.5, 0.75, 
1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, and 36.0 
hours post-dose. 
Figures 2.14 and 2.15 respectively indicate that there are some deviations in the 
sampling density curve of the standardized log(AUC) and log(Cmax) from the 
standard normal density curve. Figure 2.16 indicates that there are a fixed number of 
discrete points in the cumulative distribution curve of the standardized log(Tmax), 
which is very different from standard normal cumulative distribution curve. 
The null hypothesis of normality of log(AUC) (or log(Cmax)) is not rejected at 
0.05 significance level because P-values from Shapiro-Wilk normality test of 
log(AUC) and log(Cmax) respectively are 0.7103 and 0.0981; both are larger than 
0.05. The null hypothesis of the normality of log(Tmax) is rejected at 0.05 
significance level because the p-value from Shapiro-Wilk normality test of log(Tmax) 






Figure 2.14 Comparison of the standard normal density, empirical density and sample histogram of the 
standardized log(AUC) from 39 subjects of the real data set 
 
 
Figure 2.15 Comparison of standard normal density, empirical density and sample histogram of 





Figure 2.16 Comparison of standard normal distribution function and cumulative distribution function 
of standardized log(Tmax) 
 
2.8 Discussion and conclusions 
 
Strictly based on the statistical theory, iAUC  is not a log-normal variable even 
under the assumption that the plasma concentration ( ijC ) at each time point ( ijt ) is a 











1,5.0  , which is a 
weighted sum of log-normal random variables. The examination of the sampling 
distributions of the standardized log(AUC) for 9 cases in Section 2.5 with large 
samples shows that the sampling distribution of the standardized log(AUC) 
sometimes has heavy tails compared to  the normal distribution. But Figures 2.8 and 
2.9 in Section 2.6.1 show that the normality assumption of log(AUC) seems 
reasonable if the independent and identical measurement errors are assumed to be t 




Since Cmaxi= ( )ij
j
Cmax  from all observed values for Subject i, Cmaxi should 
depend on the expected concentration curve. Furthermore, the possible time points to 
obtain Cmaxi are limited by the sampling schedule. So Cmaxi should not be log-
normal variable even if ijC is a log-normal random variable. The examination of the 
sampling distributions of the standardized log(Cmax) for 9 cases in Section 2.5 with 
large samples shows that the distribution of log(Cmax) is obviously skewed to the 
right or the left. The 25th, 50th, and 75th percentiles of log(Cmax) are all different from 
the 25th, 50th, and 75th percentiles for the standard normal distribution, respectively. 
The close examination of the sampling distribution of the response variable for large 
sample size study provides insight into its skewness and kurtosis. The sampling 
distribution of log(Cmax) is skewed even if the independent and identical 
measurement errors are assumed to be t. Figure 2.11 in Section 2.6.2 shows that the 
normality assumptions of log(Cmax) is severely violated if there is a subpopulation 
with a slower absorption process. Figures 2.12 and 2.13 in Section 2.6.3 show that the 
sampling distribution of the sampling distribution of log(Cmax) is skewed for data 
from two-compartment model under the combinations of ξ , 0ρ , and CV in Table 2.4. 
However, the rejection rate of the Shapiro-Wilk normality test for many small sample 
size studies does not provide the significant evidence for these cases. In other words, 
the Shapiro-Wilk normality test for any small sample size study should not be 
recommended in practice as statistical evidence for proving of the validity of the 




Comparing the cases in Section 2.6.3 compared to those in Section 2.5.2, it 
appears that the sampling distribution of the response variable (log(AUC) or 
log(Cmax)) is not greatly affected by the choice of compartment modeling.  
The real example in Section 2.7 illustrates that histogram of log(AUC) or 
log(Cmax) shows some departure from normality.  
The CDF of the standardized log(Tmax) has a fixed number of mass points and is 
above the standard normal CDF for almost every scenario. Since the number of 
possible values of Tmax is limited by the number of sampling points, distribution of 
Tmax most likely is discrete, not normally distributed. 
In conclusion, the sampling distribution of log(AUC) with large samples often has 
heavy tails. The sampling distribution of log(Cmax) is skewed either to the left or to 
the right and is not robust to many perturbations studied in this chapter. Our 
examinations of the sampling distributions of log(AUC) (or log(Cmax)) for a large 
number of simulated subjects helps to identify the nature of non-normality of 
log(AUC) (or log(Cmax)). On the contrast, the rejection rate of Shapiro-Wilk 
normality test, which is not sensitive for many small samples (e.g., 40 subjects), 
cannot provide such insight. Hence it is necessary to examine the sampling 
distribution of the response variable for many more large sample size simulations 
with more extensive variation of pharmacokinetic parameters and distributions so that 
the nature of the distribution for log(AUC) (or log(Cmax)) can be further evaluated. 
We must point out the limitation of our investigation since it is based on the 
simulations generated from the pharmacokinetic compartmental models and a 




not fit the pharmacokinetic compartmental model and measurement error structure 




Chapter 3  Background of the two one-sided tests for 
univariate bioequivalence testing 
3.1 Introduction 
 
In a typical bioavailability/ bioequivalence study, a test product (T) and a reference 
product (R) are administered to subjects. The reference product could be a marketed 
innovator's product previously approved by Food and Drug Administration (FDA) 
and the test product a potential generic substitute manufactured by a different 
pharmaceutical company. The test and reference products could also be different 
formulations, but manufactured by the same pharmaceutical company.  
Assuming the response variable (log(AUC) or log(Cmax)) is normally distributed, 
Schuirmann [9] compared the two one-sided tests procedure and the power approach 
which tests the hypothesis of no difference, RTH µµ =:0 , for assessing the 
equivalence of average bioavailability in terms of rejection regions. In the 
bioequivalence evaluation of pharmacokinetic studies, the normality of the response 
variable (log(AUC) or log(Cmax)) is often assumed in practice. However the 
histograms for log(Cmax) are skewed for many simulation scenarios in Chapter 2.   
Denote the population mean bioavailability (as measured by log(AUC) or 
log(Cmax)) of the test product by Tµ and the population mean bioavailability of the 
reference product by Rµ . In order to conclude the bioequivalence of the test product 
and the reference product, we should reject the null hypothesis in the context of the 
















          (3.1). 
Here θ1 and θ2 are pre-specified constants, also called equivalence margins, and θ1< 
θ2.  
The null hypothesis, H0, states that μT and μR are not equivalent. The alternative 
hypothesis, H1, states that they are equivalent. 
The statistical hypotheses H0 and H1 given above are referred to as the “interval 
hypotheses” in the literature [10, 11]. The interval hypotheses H0 and H1 can be 
decomposed into two sets of one-sided hypotheses as shown in Section 3.3. 
The purpose of this chapter is to provide a general background for the two one-
sided testing and the power approach procedures. The power approach in practice 
usually consists of testing the hypothesis of no difference, RTH µµ =:0 , at level 0.05 
and a lack of significance is often used to incorrectly infer equivalence.  For assessing 
the equivalence of average bioavailability of the test and reference products, the 
power approach switches what ought to be the null and alternative hypotheses. The 
power approach too often frequently fails to reject the hypothesis of no difference 
with a small study size and/or larger variance, in essence rewarding the investigator 
or company for a less than adequate study. It is recognized that the power approach 
will reject RTH µµ =:0 in large studies with smaller variability, but sometimes 
RTH µµ =:0  is rejected although the two products are likely quite comparable. In 
Section 3.2, the linear mixed effect model for a two-period two-treatment crossover 
study is described in great detail. In Sections 3.3 and 3.4, the hypotheses and test 




respectively. In Section 3.5, the exact power functions for these two approaches are 
derived.  
 3.2 Linear mixed effect model for a two-period two-treatment crossover 
bioequivalence study  
 
According to the 2001 Food and Drug Administration’s Guidance for Industry [1]: 
Statistical Approaches to Establishing Bioequivalence, the Center for Drug 
Evaluation and Research (CDER) recommended that a standard in vivo 
bioequivalence (BE) study design be based on the administration of either single or 
multiple doses of the T and R products to healthy subjects on separate occasions, with 
random assignment to the two possible sequences of drug product administration. 
Hence the crossover design for an in vivo BE study is the primary design employed in 
regulatory trials. 
In a two-period two-treatment crossover design, a group of n1 subjects (Sequence 
1) receives the reference drug, and a profile of the drug concentration within blood 
plasma over time for each subject is obtained. After a washout period for removal of 
any carryover effect, this group receives the test drug and drug plasma concentration-
time profiles are again obtained. A second group of n2 subjects (Sequence 2) receives 
the drugs in the reverse order. 
As long as the two periods are sufficiently far apart it is reasonable to assume that 
there is no interaction between formulation and sequence and no carry-over effect. In 
the 2-period 2-treatment crossover study, the carry-over and interaction between 
formulation and sequence are not separately identifiable. The carry-over effect can 




the second period. A washout period is incorporated into the study design to allow a 
drug administered in the first period to be washed out of the body before the other 
drug in the second period is taken. In that way, the plasma concentration of a drug 
administered in the first period will be reduced to a negligible level in the second 
period. Hence it is reasonable to assume no carry-over effect in this crossover design. 
However, one must assume no interaction between formulation and sequence for the 
analysis since the interaction between the formulation and period is not estimable in 
the 2-period 2-treatment crossover study. In practice, if these assumptions are suspect 
an alternate study design is used where different subjects are exposed to test and 
reference product.  
Let ijkY  be the response (e.g., log(AUC)) of the k
th subject in the jth period of the ith 
sequence in the 2-period 2-treatment crossover study, where i=1, 2, j=1, 2 and k=1,.., 
ni. Then ijkY  is modeled by the linear mixed effect model  
ijkijjikijk FPSY εγ ++++= ,                                                                  (3.2) 
where γ is the overall mean; Pj is the fixed effect of period j; Fij is the fixed effect 
of the formulation administered in period j of sequence i; Sik is the random effect of 
subject k in sequence i (note: If subjects each have individual identifiers, rather than 
being labeled within sequences as in model 3.2, then Sik is replaced by Sk.); and εijk is 
the random error. From the treatment assignments, we know that F11 = F22 = Rµ  and 
F12 = F21 = Tµ . The parameters can be estimated only subject to restrictions: P1 + P2 
= Tµ  + Rµ  = 0, since otherwise the parameters P1, P2, Tµ , and Rµ  are not separately 




mean 0. The variance of Sik is 
2
Sσ  and the variance of εijk is 2Tσ  if 2,1,, =∀≠ jiji  for 
the test formulation and 2Rσ  if 2,1,, =∀= jiji for the reference formulation.  
Let RT µµθ −=
* , where Tµ  and Rµ  are the true means of the test and reference 
formulations, respectively. An estimator of 
*θ is given as  
2
ˆ 22211112 •••• −+−= YYYYD                                                                           (3.3). 
Since 
( ) ( )
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For this crossover design, D̂  is a normally distributed unbiased estimate of *θ  = 


























































The estimate D̂  is the average of the averages of the intra-subject difference 
between the test and the reference for the two sequences and 2S  is a pooled estimate 









is distributed as 2χ  with 
221 −+= nnν  degrees of freedom. 
Plugging the model value Yijk into S2, we rewrite S2 as:  












































 has a Chi-squared distribution with degrees of 


















 has a Chi-squared distribution with degrees 





























Model 3.2 is a typical model formulation for the 2-period 2-treatment 
bioequivalence study in the literature [2, 3]. Jones and Kenward’s model [3] is: 
ijkiijjikijk jIFPsY ελγ +=++++= )2( , where iλ  is the carry-over effect of the ith 
sequence; this is the same as Model 3.2 if iλ  is assumed to be zero. Another variant 




3.3 The two one-sided tests procedure 
The interval hypotheses H0 and H1 in Equation 3.1 can be decomposed into two 



























 .                                                                      (3.6) 
The two one-sided tests procedure consists of rejecting the interval hypothesis H0, 
and thus concluding equivalence of μT and μR, if and only if both H01 and H02 are 
rejected at a chosen nominal level of significance α. 

























−= θ .                                                                                             (3.8) 
 
Assuming that (1) the bioavailability is normally distributed, (2) the number of 
subjects in each sequence are equal (n1=n2=n/2), (3) there are no missing 
observations, and (4) the variance of test and reference products are equal (this 
assumption need only be approximately correct.), the test statistics for hypothesis 









































T , where θ1 and θ2 are equivalence 
margins such that θ1< θ2, and )(ναt is the upper quantile of student t distribution with 
α upper tail probability, and 2−= nν . 
3.4 Power approach 
The usual hypothesis testing of no difference as null hypothesis and nonzero 
difference as alternative hypothesis at the nominal level of significance α (e.g., 0.05) 













                                                                 (3.9) 












D ≤ , where ν=n-2 is the number of degrees of freedom. The 
bioequivalence of test and reference product is inferred. 
3.5 Power functions for two one-sided tests procedure and power approach  
3.5.1 Power function for the two one-sided tests procedure 
In the two one-sided tests procedure (See Section 3.3), the power (P1) is the 













freedom, ν. Assume that 2/21 nnn ==  and 222 σσσ == RT , we determine the power 
function ( )σθ ,,*1 nP  as follows: 


















































































































































































































































































−= , ),( 21* θθθ ∈ , )(ναt is the 1-α quantile of the ( )νt , and 
)(⋅Φ  is the standard normal cumulative distribution function. 
3.5.2 Power function for the power approach 
In the power approach (Section 3.4), the power ( ),( *1 σθ
PowerP ) is the probability 
of rejecting 0H ′  given 1H ′  is true when 2/21 nnn ==  and 








































2=  into the above equation, where X is a chi-squared random 






































































































































































Here 0* ≠θ , and )(⋅Φ  is a standard normal cumulative distribution function. 
3.6 Discussion and conclusions 
This chapter provides the general background of two one-sided tests procedure for 
bioequivalence testing. Although Shuirmann [9] compared numerical value of power 
of the two one-sided tests procedure and that of the power approach for assessing the 
equivalence of average bioavailability, he did not provide the explicit power function 
for two one-sided tests procedure. Hence this chapter derives the explicit power 
functions for two one-sided tests procedure and the power approach. The two one-
sided tests procedure is much more widely used than the power approach and is the 




fundamental understanding of the difference between the two one-sided tests 





Chapter 4  Exact calculation of power and sample size 
in bioequivalence studies using two one-sided tests 
4.1 Introduction 
 
In Chapter 3, two approaches for testing bioequivalence in the context of a 
crossover design are described. We indicate that the approach based on two one sided 
tests is most commonly used in practice for the purpose of establishing 
bioequivalence.  
As we described in Chapter 3, we reject the null hypothesis in the following 














          (4.1). 
In this chapter, we describe various approaches to determine power and sample 
size in this setting.  
Since Owen’s Q function has been widely used, we would like to give a brief 
description about Owen’s Q function and how to use it for calculating the probability 
of rejecting the null for the two one-sided tests procedure for the crossover 
bioequivalence study. Owen’s Q function [35] is defined as: 



































dxxGxG , f is degrees of freedom, δ is noncentrality parameter, and c is 
upper integration limit. With Owen’s Q function, the probability of rejecting the null 
for the two one-sided tests procedure for the crossover bioequivalence study is equal 
to ( )( ) ( )( )ctQctQ vv ,0;,,0;, 12 δνδν αα −−  (see Equation (11) on Page 439 of [35]) under 
2/21 nnn ==  and 
222 σσσ == RT . Here 
22  and RT σσ are the variance for the test product 
and the reference product, respectively; 21  and nn are respectively the number of 


























In 1990, Phillips [36] calculated the power and the sample size for the two one-
sided tests procedure with equivalence margins (θ1 =-20% and θ2 =20%) for 
bioequivalence assessment of normal data based on Owen’s special case of bivariate 
noncentral t-distribution [35] and presented some sample size tables and power 
graphs. We note that Phillips did not provide the formula for calculating R (an 
argument in Owen’s Q function) in his method. (See pages 138 and 139 of [36].) 
Phillips’ [36] calculations were for equivalence margins 12 θθ −=  =0.20, different 
from the values 12 θθ −=  = log 1.25 = 0.2231 recommended in [1], the FDA 
Guidance for Industry. In 1991, Diletti, Hauschke, and Steinijans [37] determined the 
sample size for the two one-sided tests procedure with equivalence margins (θ1 
=log(0.8) and θ2 =log(1.25)) for bioequivalence assessment of one log-transformed 
response variable that is assumed to be normally distributed on the basis of Owen’s 




not provide the formula for calculating c (an argument in Owen’s Q function) in their 
method. (See Page 5 of [37].) They presented the graphs of the power against the 
number of subjects for various coefficients of variations (standard deviation divided 
by the mean) of the untransformed data. There are graphs for the above probability 
but no explicit formula for this probability [36, 37]. In 1992, Liu and Chow [38] 
derived approximate sample size formulas for two one-sided tests procedure with 
equivalence margins θ1 =log(0.8) and θ2 =log(1.25) for bioequivalence assessment of 
one log-transformed response variable that is assumed to be normally distributed. 
These margins correspond to the margin in the 2001 Food and Drug Administration’s 
Guidance for Industry [1]. Hauschke, Steinijans, Diletti, and Burke [39] compared the 
sample size based on Owen’s bivariate noncentral t-distribution and an approximate 
formula in the case of a multiplicative model, in which period, treatment effect, 
subject effect, and residual acts proportionally on AUC or Cmax. Taking logarithms 
of both sides in the multiplicative model transforms the multiplicative model on the 
original scale to the additive model (in which the different components affected the 
response variable additively) on the logarithmic scale. In 1999, Kieser and Hauschke 
[40] proposed a unifying approach to approximate sample size determination for 
different types of hypotheses formulated in terms of ratio of two means and 
difference of two means for the situations of testing noninferiority, superiority, or 
equivalence when the response variable is normally distributed.  In 2000, Kieser and 
Hauschke [41] proposed an approximate sample size formula using both inter-subject 
and intra-subject variability for demonstrating equivalence in crossover trials based 




approximate formulas for sample size calculation under a balanced crossover design 
with equal variances of the test and reference products and a parallel design with 
normally distributed raw data or normally distributed log-transformed data.  
In 2007, Hauschke et al [43] published an explicit formula using Owen’s Q 
function [35] with properly defined noncentrality parameters and R under 
2/21 nnn ==  and 
222 σσσ == RT . In 2009, Phillips [44] published an explicit formula 
for the probability of rejecting the null for the two one-sided tests procedure for the 
crossover bioequivalence study under 2/21 nnn ==  and 
222 σσσ == RT . Hauschke et 
al [43] and Phillips [44] provided a clearer explanation for what these same authors 
had essentially done in 1991 and 1990, respectively. However, Phillips [44] is newly 
augmented with references to a specific readily available R-package [45]. There have 
also been several published approximations [38-42] that have been used in practice. 
In 2008, the formula for power calculation on the left side below Figure 4 on Page 
252 of [46] is the difference of cumulative noncentral t function, which is 
approximate. In 2014, the formula in Line 5 in Section 2.2 of [46] multiplied by 
Equation (2) in Section 4 of [46] for sample size calculation at nonzero true mean 
difference of the test and reference products same as Chow and Wang’s 
approximation is still used. Equation (1) in Section 2.2 of [47] multiplied by Equation 
(2) in Section 4 of [47] for sample size calculation at zero true mean difference of the 
test and reference products is also the same as Chow and Wang’s approximation. In 
2014, Shen, Russek-Cohen, and Slud published the exact power formula for 
calculating the probability of rejecting the null for the two one-sided tests procedure 




work in this chapter. The main purpose of [48] is to explain clearly just how 
untenable the approximations are for realistic parameter combinations and how easily 
the self-contained power expressions, that have been essentially known since Owen's 
1965 paper [35] are to implement in R. 
We note that except for [48] all of these approaches, both exact and approximate, 
assume the variances 22 RT σσ =  are homogeneous, that the design is balanced 
( 21 nn = ), and that measures of bioavailability (log(AUC) and log(Cmax)) are 
normally distributed. In this chapter, we compare approaches when the data is 
normally distributed and in Chapter 6 we will address the sensitivity of the exact 
method to the assumption of normality.  
In Section 4.2, we briefly derive the joint density function of test statistics and the 
exact formula for the power of the two one-sided tests procedure for testing 
bioequivalence based on a univariate normally distributed response variable. Our 
derivation for the exact power under general parameters just serves for completeness 
and for expository purposes since the explicit power formula assuming the equal 
variances for the test and reference products and balanced design was published in 
[43, 44]. However, by allowing for unequal variances, it might allow the user to 
assess the robustness of the power and sample size determinations when this 
assumption is violated. Modest differences in variability may not cause concern when 
the bioequivalence question is being addressed.  
In Section 4.3, we compare the simulated values with the numerical values and 
indicate how numerical integration easily provides accurate numerical values for 




method with the graphed power values of Diletti et al. [37], the power values graphed 
by Phillips [36] for θ2 =-θ1=0.20, and the sample size and power values generated by 
the approximate method of Chow and Wang [42]. 
4.2 Exact power function and the joint probability density function of test statistics 
(T1 and T2 ) 
 
From Section 3.2 in Chapter 3, we recall that D̂  is a normally distributed unbiased 
estimate of RT µµθ −=
























is distributed as 2χ  with 221 −+= nnν . 
























−= θ  defined in Section 
3.3 in Chapter 3 testing for hypotheses (4.1).  To correct the mis-statement of Liu and 
Li [49] that the test statistics (T1 and T2) do not have a joint density (see first two lines 
after Equation (3) in [49]), we simply observe that the function mapping ( D̂ , 2S )  to 
(T1, T2) , with domain (-∞,∞)×(0,∞)  and range { (t1, t2):  t1 > t2 }, is both 
differentiable and differentiably invertible, while the independent variables D̂  and 
2S  have respective normal and Gamma densities, as described above. (For an 
exposition of the change-of-variable formula for differentiable one-to-one 
transformations of random vectors with a joint density, see Formula 4.3.2 on Page 
158 and Theorem 2.1.8 on page 53 of [50]). The joint density for (T1, T2) can also be 




the joint cumulative distribution function derived and published by Owen [35, Sec. 
5]). 
The joint pdf of (T1, T2) is given by 


















































































































































, where 21 tt > .   (4.2) 
Although the exact power function can easily be developed as a double integral 
from the joint pdf of T1 and T2, we will derive a simpler form of the exact power 
function by integrating the conditional power given 2S . This alternative formula, in 
the same spirit as formula (11) in Section 5 of [35], is simpler because it involves 
only a univariate integral over a bounded interval, after recognizing that the 
conditional power given 2S  is a readily evaluated normal tail probability. 
The exact power function can be written, in terms of the α and 1-α quantiles tν(α)  






























































































This last expression is the expectation over S of the conditionally normal probability 























































































)(ναt is the 1-α quantile of the t-distribution with 221 −+= nnν  degrees of freedom 
























⋅ ~ ( )νχ 2 , we write 


















































































−= and 0, >RT σσ . 
The gamma density and integrand written in terms of the normal cdf are readily 
evaluated, so the integral (4.3) is easily evaluated in any good statistical computing 




In the two one-sided tests procedure for one single variable, the power (P1) is the 
probability of rejecting H0 when Ha in (4.1) is true. For sample size determination and 
power of two one-sided tests procedure in the bioequivalence literature, Schuirmann 
[9], Phillips [36], Diletti et al. [37], and Chow and Wang [42] all assumed 
that 2/21 nnn ==  and 
222 σσσ == RT .  Following this convention, we will compare the 
exact power with Chow and Wang’s approximate power under the assumption 
that 2/21 nnn ==  and 










































































c  and 0>σ . 
4.3 Comparison of power values from the exact power function and Monte Carlo 
simulations  
 
The power values computed numerically from (4.4) using a standard numerical 
integration routine, integrate in  R [51], were carefully checked both in terms of their 
own estimated error bounds and by comparing with Monte Carlo simulations of 
rejections in the two one-sided tests procedure. Table 4.1 lists the results from the 
exact power function and Monte Carlo simulations.  From Table 4.1, we found using 
106 Monte Carlo replications (with corresponding simulation standard errors less than 
0.0005), for a combination of cases of *θ  equal to 0, 0.1, 0.2 and log(1.25), and of σ 
= 0.2 and  0.3, that the simulated and exact values were always within 0.001 of one 
another, and that the numerical integration error bounds were less than 0.0001 




Since ( )νν α2t  is an increasing function of ν  (see the proof in Appendix 4.2), both 
the upper limit of integration and the integrand in the integral formula (4.4) are 
directly seen to be monotone increasing as a function of n, so the integral (4.4) itself 
is also monotone increasing in  n. Hence we use a bisection search or other numerical 
root-finder to find the required sample size n  by first solving for the continuous value  
n at which the exact power (4.4) with all parameters held fixed is equal to power (1-β) 
and then rounding it up to the smallest even number n ≥ n*. Code lines for doing this 
in R are also supplied in Appendix 4.1. 
Table 4.1 Comparison of power values from the exact power function and Monte Carlo simulations for 
n=40  
*θ  σ  Power 
Exact power (upper bound on 
absolute error) by Equation (4.4)  
Monte Carlo 
Simulations (106) 
0 0.2 0.9988604 (1.8e-6) 0.9989 
0.1 0.2 0.8552369 (1.8e-6) 0.8554 
0.2 0.2 0.1278706 (3.4e-7) 0.1285 
log(1.25) 0.2 0.0500 (7.3e-8) 0.0496 
0 0.3 0.8950818 (6.1e-8) 0.8946 
0.1 0.3 0.5617662 (1e-7) 0.5622 
0.2 0.3 0.09578144 (7.4e-8) 0.0955 
log(1.25) 0.3 0.04999948 (8.9e-5) 0.0499 
4.4 Comparison of exact power with power values from graphs and approximate 
power 
4.4.1 Comparison of exact power function with approximate power function of Chow 
and Wang 
4.4.1.1 Approximate power formulas of Chow and Wang 
 
Chow and Wang [42] focused on the log-normally distributed data which can be 
modeled by the linear mixed effect model (3.2). When 0* >θ  and *θ is large relative 





































































PP . Comparing the 
right sides of the two formulas, we can easily see that Chow and Wang’s power 

















θθνθ α . 
Chow and Wang replaced S by the 2σ  in the right side of inequality of PCW, so 
they further approximated the power function (4.4) when 0* >θ  and *θ is relatively 






















PP .     
(4.5) 
Hence the sample size can be determined by 
( ) ( )( )













Chow and Wang used similar treatments for obtaining approximate power when 
0* <θ . Hence Chow and Wang concluded that the sample size can be determined by 
( ) ( )( )












n     (4.6). 






















 if θθθ =−= 12 . Hence the sample size is 
determined by 













n  (4.7). 
4.4.1.2 Comparison of exact power and approximate power of Chow and Wang 
 
The approximate power function of Chow and Wang [42] tends to overestimate 





, but due to the further 






their approximation does not overestimate for all possible parameter combinations. 
The differences between exact power and approximate powers are illustrated in 
Figures 4.1 to 4.4 for wide ranges of standard deviations and true mean differences.  
 
As defined in Section 4.2, σ2 is the variance of log-transformed data from the 
reference product. It is well known that the relationship between the coefficient of 
variation (CV) in the untransformed data and the standard deviation (σ) of the log-
transformed is 1
2
−= σeCV . 
When σ =0.3 for log-transformed data, CV=0.307 for untransformed data. It is well 
known that the product is a highly variable drug when CV for untransformed AUC or 
Cmax is greater than 0.3 [52, 53]. Regardless of the magnitude of the standard 
deviation σ from examination of many numerical results, Chow and Wang’s 




very small.  Chow and Wang’s power curve has a peak since Chow and Wang used 
two different formulas for power when θ* is zero and nonzero. The difference 
between the Chow and Wang’s approximate power and the exact power will decrease 
as the total sample size increases for same σ and n, and also decreases as the true 
difference (θ*) increases. When σ increases from 0.2 to 0.7, there are more cases 
when Chow and Wang’s approximate power exceeds the exact power. 
Thus, sample sizes estimated by Chow and Wang’s approximate power for the 
combination of small n and small θ* are underestimated. When studies are 
underpowered, they may fail to meet the study objectives. For combination of large 
θ* and small n, Chow and Wang’s approximate power can underestimate the true 
power slightly, which results in having a few more subjects than necessary.  
Previous authors [36, 37, 42] often focused on CV<0.3. However, errors of 
approximation may also be important for the large σ values of highly variable drugs.  
From Figures 4.1 to 4.4 there are more combinations of θ* and n for which Chow 
and Wang’s approximate power over-estimates the exact power as σ increases from 
0.2 to 0.7.  
From Figure 4.1, it is seen that Chow and Wang’s approximate power is very close 
to the exact power for n≥18 and θ*>0.04 when σ= 0.2. 
From Figure 4.2, it is seen that Chow and Wang’s approximate power over-
estimates the exact power for many combinations of θ* and n when σ= 0.3. For 
example, Chow and Wang’s approximate power is 81.77%, our exact power is 
74.13%, and Chow and Wang’s approximate power over-estimates the exact power 




From Figure 4.3, it is seen that Chow and Wang’s approximate power over-
estimates the exact power for many combinations of θ* and n when σ= 0.4. For 
example, Chow and Wang’s approximate power is 80.35%, our exact power is 
71.63%, and Chow and Wang’s approximate power over-estimates the exact power 
by about 9% for n=50 and θ*=0.02 when σ= 0.4. 
From Figure 4.4, it is seen that Chow and Wang’s approximate power over-
estimates the exact power for many more combinations of θ* and n when σ= 0.7 than 
those when σ= 0.2. For instance, Chow and Wang’s approximate power over-estimate 
the exact power by 10% for n<140 and small θ* when σ= 0.7. 
 
Figure 4.1 Comparison of Chow and Wang’s approximate power and exact power numerically 
calculated from Equation (4.4) against and true mean difference, θ* when σ=0.2, at different total 





























Figure 4.2 Comparison of Chow and Wang’s approximate power and exact power numerically 
calculated from Equation (4.4) against and true mean difference, θ* when σ=0.3, at different total 
















































Figure 4.3 Comparison of Chow and Wang’s approximate power and exact power numerically 
calculated from Equation (4.4) against and true mean difference, θ* when σ=0.4, at different total 




















































Figure 4.4 Comparison of Chow and Wang’s approximate power and exact power numerically 
calculated from Equation (4.4) against and true mean difference, θ* when σ=0.7, at different total 


















































4.4.1.3 Comparison of exact sample size and approximation of Chow and Wang 
 
In Table 4.2, we compare the total sample sizes from Equation (4.4) and Chow and 
Wang’s approximate power [42] for achieving 80% power. The total sample size is 
rounded to next even number. Table 4.2 shows that the difference in the total sample 
sizes increases as σ increases, and decreases as 
*θ increases, for each given *θ . For 
example, the total sample size from the Chow-Wang approximate power is about 
10% less than that from exact power when 
*θ =0.03 and σ=0.2; about 15% less when 
*θ =0.02 and σ=0.4; and about 20% less than that from exact power when *θ =0.01 
and σ=0.3. 
Table 4.2 Comparison of sample size from exact power given by Equation (4.4) and Chow and 
Wang’s approximate power for achieving 80% power at different combination of σ and θ* 













0.1 6 6 6 6 6 6 6 6 
0.2 16 14 16 14 18 16 18 18 
0.3 34 28 34 30 36 32 38 36 
0.4 58 46 60 50 62 56 66 62 
0.5 90 70 92 78 94 86 100 94 
0.6 128 100 130 110 136 122 144 136 
0.7 172 136 176 150 184 164 194 184 
4.4.2 Comparison of the exact power and Diletti et al.’s power  
 
Since Diletti et al [37] did not provide the explicit mathematical formula for power 
calculation, we read three power values from Fig. 1c of [37]. The exact power values 







Table 4.3 Comparison of the exact power given by Equation (4.4) and power values read from Fig. 1c 




0 Log(1.05) Log(1.1) 
Diletti et al’s power 0.97 0.9 0.7 
Exact power, ( )σθ ,,*1 nP  0.9679 0.902 0.696 
 
From Table 4.3, the power is very close to the exact power by Equation (4.4). 
However, the graphs and tables present a limited number of cases. For instance, 
Diletti et al. [37] did not provide any power value for CV>30%, as would be the case 
with highly variable drugs. The exact and explicit power function allows such 
situations to be considered. 
4.4.3 Comparison of the exact power and Phillips’ power  
 
Since Phillips [36] did not provide the explicit mathematical formula for his power 
calculation, we also read three power values from Fig. 3 of [36]. The parameters we 
choose and comparison of the exact power values by Equation (4.4) and power values 
from Fig. 3 in Phillips’ paper under these parameters are listed in Table 4.4. In 
Phillips’s paper, θ1 =-20% and θ2 =20%.  In order to compare the exact power, 
( )σθ ,,*1 nP , with Phillips’s power, θ1 =-20% and θ2 =20% are assumed in the 
calculation of exact power function, ( )σθ ,,*1 nP . 
Table 4.4 Comparison of the exact power given by Equation (4.4) and power values read from Fig. 3 




0.015 0.05 0.1 
Phillips’ power 0.9 0.8 0.5 





From Table 4.4, Phillips’ power is very close to the exact power by Equation (4.4). 
However, the graphs and tables present a limited number of cases as Phillips [36] did. 
The exact and explicit power function, such as 1P  in equations (4.3)-(4.4), allows any 
situation to be considered. 
4.5 Discussion and Conclusions  
 
The exact power can be derived from the joint density function of two highly 
correlated test statistics (T1 and T2). Our derivation for the exact power under the 
general parameters just serves for completeness and for expository purposes since the 
explicit power formula under the equal variance for the test and reference product and 
a balanced design was published in [43, 44]. The exact power numerically integrated 
from Equation (4.4) is corroborated by the results from 106 Monte Carlo simulations. 
Since suitable free software, such as R software, is available, exact power for the two 
one-sided tests procedure can be readily obtained from the power function by 
numerical solutions. Our R code for power function is attached in the Appendix 4.1. 
Exact sample size calculation is then easy using the exact power for any parameter 
combinations in bioequivalence studies based on two one-sided tests. This chapter is 
to remind the readers that approximate methods are still in use [46, 47]. The exact 
power will pave the way for sample size calculation for any parameters’ combination 
(e.g., unequal variance of the test and reference products) in bioequivalence study. 
The fact that Chow and Wang’s approximate power markedly over-estimates the 
exact power for many combinations of θ* and n as shown in Figures 4.1 to 4.4 and 
Table 4.1 demonstrates the preferability of the exact power function ( )σθ ,,*1 nP  in 




differences in log(AUC) or log(Cmax) as small as 0.03 are of practical interest based 
on the review by Davit et al. [54] of 12 years of bioequivalence studies from the 
FDA, which found that more than 50% of studies have mean difference less than of 
0.05 between generic product and innovator. (These are mean differences in 
log(AUC) or log(Cmax), when the corresponding mean differences in AUC and Cmax  
between generic and innovator products are respectively 3.56%  and  4.35%.) 
While the exact power agrees closely with [36, 37] in the few cases displayed in 
those papers and the explicit formula under the equal variance for the test and 
reference product and balanced design was published in [43, 44], it is still important 
to have exact powers and sample sizes in all bioequivalence study settings, including 
those for unequal variance of the test and reference products and to show just how far 
off the approximate formulas that are still in use [46, 47] can be for many practical 
settings. 
Appendix 4.1: R code for exact power and sample size 
 
The power ( )RTnnP σσθ ,,,, 21*1  in (4.3) is calculated by the following lines of R 
code. Here the arguments n1 and n2 respectively represent the sample sizes 21, nn of 
sequences 1 and 2; sigT , sigR represent Tσ  and Rσ ;  th1  and  th2 respectively 
represent 1θ  and 2θ ; and  tstar represents 
*θ . In fact, ( )RTnn σσ ,,, 21   enters formula 
(4.3) only through the quantities ( ) 4//1/1)( 21222ˆ nnTRD ++= σσσ   and   
221 −+= nnν , and arguments sigD and nu represent D̂σ  and ν.  Pow1$value is the 
power in formula (4.3) (with Pow1$abs.error  the estimated absolute error of 




beta.  We use two standard R functions: integrate to perform univariate numerical 
integration, and uniroot to perform root-finding or inversion. 
Pow1 = function(sigD, nu, th2,th1,tstar, alpha=.05){ 
     Integrand = function(x)    { 
         (pnorm((th2-tstar)/sigD- qt(1-alpha, nu)*sqrt(x/nu))-  
         pnorm((th1-tstar)/sigD+ qt(1-alpha, nu)*sqrt(x/nu)))*dchisq(x,nu)     
     } 
     integrate(Integrand, lower = 0, upper =  
              nu*((th2-th1)/(2*qt(1-alpha, nu)*sigD))^2)[1:2] 
}  
 
    SSiz = function(beta, sigT,sigR,th2,th1,tstar, alpha=.05, uppern=300){ 
         Pow2 = function(n) { 
             Pow1(sqrt((sigT^2+sigR^2)/n), n-2, th2, th1,  tstar, alpha)$value-1+beta } 
         uniroot(Pow2,c(3,uppern))$root 
    }  
Appendix 4.2: Proof of monotonicity of ( )νν αt  
 
Define ( ) ( )ννν YZt = , where Z is the standard normal random variable and 









iZY , where νZZZ ,...,, 21 are independent and identical standard normal 




means for any real value x , ( )( ) ( )( )xYPxYP ≥>≥+ νν 1 . If a function ( )yzf ,  is 
monotone decreasing in its second argument and Z is a random variable independent 
of ( )21,YY  with 1Y stochastically larger than 2Y , then ( )2,YZf  is stochastically larger 
than ( )1,YZf . From this it follows that ( ) 11 ++ ννt is stochastically smaller than 
( ) ννt , from which it follows that. ( ) ( ) νννν αα tt <++ 11 . Therefore, 




Chapter 5  Two-stage sample size re-estimation for 




As previously discussed in Chapter 3, the goal of a bioequivalence study is to 
establish that two product formulations (T for the test product and R for the reference 
product) are sufficiently similar with respect to the mean bioavailability (log(AUC) or 
log(Cmax)). In this setting, we should reject the null hypothesis in the following 














 .                                                (5.1) 
In this chapter as in previous chapters, we assume the basic study involves a 
crossover design in which each patient is exposed to each formulation, though the 
order of which formulation comes first is randomized. The sample size calculation to 
achieve a specific power is described in Equation (4.3) of Chapter 4 for a single 
planned stage. In general planning these studies requires specification of the assumed 
mean difference between the test and the reference products and variances of the test 
and reference products. Misspecification of either mean difference or variances can 
result in an under-powered or over-powered trial. Both the assumed mean difference 
between the test product and the reference product and variances of the test and 




which some factors could be different from those in the current study. So sample size 
re-estimation can be important in improving the chances for success in a study. Most 
sample size re-estimation procedures for superiority clinical trials [55, 56] and for 
bioequivalence crossover trials [46, 47] are based on the updated variance estimates 
from an internal pilot study (Stage 1) since naturally Stage 1, a subset of the current 
trial’s data, is more similar to the current data than any historical data. Stein's classic 
two-stage design [55] assumed  that the number of subjects in Stage 2 ought to 
depend on the variance estimated from Stage 1 and Stein’s procedure [55] used only 
the Stage 1 variance estimate 21S  in the final statistic. This provided a guarantee of 
being able to control the type I error rate while the type II error rate would be no 
higher than a specified level irrespective of the true variance. Wittes et al [56] used 
the Naïve t for the combined data from Stage 1 and Stage 2 in which the number of 
subjects depended on the unblinded variance estimate from Stage 1 and they found 
out that the type I error rate was inflated. Potvin et al. [46] considered a simple naïve 
sample size re-estimation method using the nominal α (e.g., 0.05) at whichever stage 
the test is carried out and using data from both stages (if two stages are carried out) to 
compute the final variance estimate for two-period two-treatment crossover 
bioequivalence trials. Their limited simulations [46] quickly confirmed that the 
overall type I error rate can be much larger than the nominal level α . To investigate 
the type I error of the unmodified t-test after a blinded sample size revision in 


















































































Here lin  is the sample size of the i
th sequence at the lth stage 2,1, =∀ li , 
21 lll nnn +=•  is the total sample size at the lth stage, lD̂  is the average of the intra-
subject difference between the test and the reference over subjects and crossover 
sequences in Stage l, 2lS  is a pooled estimate of 
22








































is the mean period difference of Sequence i at Stage 2. Golkowski et al. proposed to 
re-estimate •2n with the following formulas in which 
22
RT σσ +  was replaced by the 
blinded variance estimate 2ˆOSσ :  
























for 00 >θ and 























for 00 =θ . 





















σ , 0θ  (the assumed mean difference)  is in practice 
assumed to lie between log(0.9) and log(1.1), 2θ  (the equivalence margin) equals  log(1.25), 
ikd1  is the difference between Period 2 and Period 1 for the k




sequence at Stage 1, and 1d is the mean of the period differences of two sequences at 
Stage 1. Golkowski et al. [47] calculated the t-test statistic from the combined data of 
Stage 1 and Stage 2 by 
( ) ( )


















, a function of four 
components *2211  and , , , VZVZ  whose distributions were discussed in detail on page 
1003 of [57]. The type I error rate 
DH
act
01α  for which they claimed as the actual type I 
error rate under the null hypothesis DRT
DH 101 : δµµ ≤−  (see pages 1004 and 1005 of 
[45]) is an approximation, not the exact value due to the following two reasons: 1) 
The distribution of *2V  given ( 11  ,VZ ) in [57] is approximately Chi-squared; 2) The 
boundaries of the integrations over the rejection region for calculating the maximum 
type I error rate are unclearly specified. Golkowski et al. [47] showed that their 
proposed sample size re-estimation procedure, although blinded, can lead to some 
inflation of the type I error rate. Furthermore, Golkowski et al. [47] proposed to 
adjust the actual type I error rate such that for the particular sample size of the 
internal pilot study 1n , the maximum type I error rate falls below the nominal α. The 
actual type I error rate for bioequivalence in Golkowski et al. [47] is approximate 
(possibly masking a minor type I error level inflation) since the distribution that they 



















































































 are no longer independent conditioning on both 1V  and 1D̂  [58].  
Let ( ) 211 2 SnX −= • . The new sample size ( )( )Xnn •• + 21  is a random variable 
because it is calculated using 21S  (the estimated variance) from Stage 1.Therefore 

















ˆ θ  and 

















ˆ θ  will not follow the standard t-
distribution under the null hypothesis. Here D̂  and S  are respectively the average of 
the intra-subject difference between the test and the reference over subjects and 
crossover sequences and the pooled estimate of the variance of an intra-subject 
difference from the combined data of both Stage 1 and Stage 2. The quantities 
( )Xnn 2111 +  and ( )Xnn 2212 +  are respectively the number of subjects in Sequence 1 
and Sequence 2 of the combined data of Stage 1 and Stage 2. Consequently the type I 
error rate in sample size re-estimation [46] cannot be controlled at the nominal level 
α  if the naïve ( )( )221 −+ •• Xnntα  is used when combining data of two stages. 
In the literature and in practice, the point estimate for the variance obtained at stage 1 
is often used for sample size re-estimation. Following this practice, we propose that 
the number of subjects added to the second stage should be based on the point 




using the pooled variance of Stage 1 and Stage 2 in the final statistics [59], we 
propose to replace S  in 21T  and 22T , by














that the exact critical value for the two-stage study can be derived analytically. Two 
new test statistics for the hypothesis testing based on the combined data of Stage 1 




















ˆ θ  and 




















ˆ θ .  
We will compare 22T  and 
*
22T  in Section 5.7 and provide justification for the use of 
*
22T . 
Let 20S  be the initial value for 
22
RT σσ +  from the historical data. Throughout this 
chapter, we assume that 20S  is a constant, not a random variable. Let 
*θ  be the true 
mean difference between the test product and the reference product ( RT µµ − ). We 
also let 0θ  be the assumed mean difference between the test product and the reference 
product for power calculation. Since the probability of rejecting 0H  under aH  in 
Equation (5.1) when we assume that 20S  is the true variance (
22
RT σσ + ) and 
*θ = 0θ  is 
0p  (targeted power), •1n  is calculated for any given allocation ratio of two sequences 






















































































































































 and 212111 −+= nnν . 
If ( ) 201 2 SnX −≤ • , then we stop at the end of the first stage. We use the following 
































DT θ  to 
test the hypothesis in Equation (5.1) at Stage 1. Thus the data from the first stage is 
analyzed by comparing 11T  and 12T  to the critical value ( )1ναt  and - ( )1ναt , 
respectively. 
To simplify the notation for 22 RT σσ + , we define 
22
RTV σσ += . 
Let ( )VnnP s ,,, 121121 θ  be the joint probability of rejecting 0H  in Equation (5.1) under 
0H  for one-stage study and ( ) 201 2 SnX −≤ • .  ( )VnnP s ,,, 121121 θ  is calculated by (5.3) in 
which 2



























































































































































 and 212111 −+= nnν . 
 α  is the significance level for Stage 1 analysis, and 212111 −+= nnν . See its 
derivation in Section 5.5.1. 
If ( ) 201 2 SnX −> • , then ( )Xnn •• + 21  is calculated to assure that the combined study 
(using Stages 1 and 2) will have the targeted power 0p . From this point forward, 
( )Xn •2  is a function of X.  This assumes that 21S  is 2V  and 0θ  is *θ  for any given 
allocation ratio of two sequences ( ( )( ) ( )( ) 1.,. 22122111 =++ XnnXnnge ) and we solve 
the following equation for ( )Xn •2 : if ( ) 201 2 SnX −> • , then 
























































































































σ , and ( ) 221 −+= •• Xnnν .  
The solution of Equation (5.4) for ν  is unique (see Proposition 5 in Section 5.5.3).  
Clearly, ( )Xn •2  is a continuous-valued function implicitly defined in Equation (5.4). 
Actually in practice ( )Xn •2  is rounded up to next even number. This is a naïve and 




sample variance was not observed and that the second stage sample size was fixed in 
advance at ( )Xn •2 . 
To illustrate the idea, we assume that 05.00 =θ , 9.00 =p , ( )25.1log12 =−= θθ , 
05.0=α , 1211 nn = , and ( ) ( )XnXn 2221 =  throughout this chapter. From Equation 
(5.4), it can be seen that •2n  is a function of X . 
Let ( )upVnnP s ,,,,, 0121122 θ  be the joint probability of rejecting 0H  in Equation 
(5.1) under 0H  for two-stage study ( ( ) 02 >• Xn ) and ( ) 201 2 SnX −> • . Then 

















































































 . (5.5) 
See its derivation in Section 5.5.2.  Here u is the critical value.  
( ) ( )( ) ( ) xxcxnnxaa −−+== •• 2221 4 .                                 (5.6)  
( ) 201 2 Snb −= • .                                                                 (5.7) 






















.                 (5.8) 



























































.  (5.10) 
If ( ) 201 2 SnX −> • , we proceed collecting the data from additional ( )Xn •2  subjects 
and then analyze the combined data from both Stage 1 and Stage 2 using the test 
statistics: *21T and 
*
22T  compared to critical values αu  and - αu  respectively. The exact 
critical value, αu , is derived as the largest value of u for which  the condition: 
( ) ( )[ ] αθθ α ≤+ upVnnPVnnP ss
V
,,,,,,,,max 0121122121121  holds. Therefore αu  is not a function of V 
or X. This property ensures the experimentwise type I error rate in the sample size re-
estimation procedure.  
In Section 5.2, we will next apply the linear mixed effect model (3.2) defined in 
Chapter 3 to both Stage 1 and Stage 2 and derive the distributions of 1D̂  and 2D̂  given 
X . In Section 5.3, we present the test statistics ( )2221  and TT  based on our two-stage 
sample size re-estimation procedure and discuss the challenge of controlling the type 
I error rate with these statistics. In order to develop the analytical solution of type I 
error rate, we propose two simpler test statistics ( *21T  and 
*
22T ). In Section 5.4, we 
describe the overall strategy for assuring that our proposed unblinded sample size re-
estimation procedure has an exact α experimentwise type I error rate. In Section 5.5, 
we derive the exact power function ( )upVnnP s ,,,,, 01211*2 θ  of *21T  and *22T  for the two-
stage study and the exact power function ( )VnnP s ,,, 1211*1 θ  for a one-stage study. In 
Section 5.6, we derive the exact critical value αu  for 
*
21T  ( and - αu  for 
*
22T ) for the 




0H  under 0H  for the two-stage study over the whole range of true variances is less 
than or equal to α . The critical value ( )1ναt  will be used for the one-stage study. In 
Section 5.7, we will show that our proposed test statistic *22T  performs much like 22T  
if the difference in the period effect between Period 2 and Period 1 is similar for both 
stages. Specifically, we compare the null and alternative distributions of 22T  and 
*
22T  
for two-stage study.   
5.2 Linear mixed effect model  
 
Recall that ijkY  is the response of the k
th subject in the jth period of the ith sequence 
in the 2-period 2-treatment crossover study, here i=1, 2, j=1, 2 and k=1,.., in1 for Stage 
1 and  k= 11 +in  ,.., ( )Xnn ii 21 +  for Stage 2. Then as in Section 3.2, ijkY  is modeled by 
the linear mixed effect model (3.2).  
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From the derivations in Section 3.2, 1D̂  is a normally distributed unbiased estimate of 















σ , and 
2V
X
 is distributed as 2χ  with the degrees 




For Stage 2, ( )
( )






























1ˆ  and 












































































For Stage 2, given sample sizes ( ) ( )XnXn 2221  and , 2D̂  is a normally distributed 















σ , and 
conditional distribution of 






 given X is 2χ  with the degrees 
of freedom ( ) ( ) 22221 −+ XnXn . Hence the distributions of 2D̂  and of 






 can be respectively obtained by averaging the conditional 
cumulative distribution function over X  with respect to its density.  
5.3 Proposed test statistics 
 
As discussed in the introduction of this chapter, random variables ( )Xn21  and 
( )Xn22  are a function of 211SX ν=  from the first stage data, so 21T  and 22T  do not 
follow the standard t-distribution under the null. Consequently, the type I error rate in 
sample size re-estimation [46] cannot be controlled at the nominal level α  if the 
naïve choice ( )( )221 −+ •• Xnntα  is used as the critical value for combined data from 












































ˆ θ  for hypothesis test (5.1) using the 













S  and *21T  and 
*
22T  can be decomposed as functions of three components:  ,1Z   ,2Z X , and 
2













−= • , i=1,2;  1Z is a standard normal variable; 
 2Z conditioned on X is a standard normal variable, ~
2VX ( )12 νχ , and 
22
22 VSν conditioned on X ~ ( )22 νχ .  
5.4 Unblinded sample size re-estimation procedure with exact power functions 
 
In general, most bioequivalence trials are unblinded. So we proposed an unblinded 
sample size re-estimation procedure described in Section 5.1 in which we compared 
*
21T  with the exact critical value αu  and 
*
22T  with - αu  for the two-stage study. The 
exact critical value, αu , is derived as the largest value of u for which  the condition: 
( ) ( )[ ] αθθ α ≤+ upVnnPVnnP ss
V
,,,,,,,,max 0121122121121  holds.  
To assure the experimentwise type I error rate ( ( )VnnP s ,,, 121121 θ  + 
( )upVnnP s ,,,,, 0121122 θ ) at exact α value, we calculate  ( )VnnP s ,,, 121121 θ  and 
( )upVnnP s ,,,,, 0121122 θ  from the exact power function using the numerical method 
which will be described in Section 5.6.2. We also quantify all levels of errors for the 




interval { }eb VVVV ≤≤:  in Section 5.6.3 and make sure the sum of all levels of error 
is no larger than 410−  
5.5 Exact power function for the proposed test statistics 
 
In this section, we first derive ( )VnnP s ,,, 1211*1 θ  and ( )upVnnP s ,,,,, 01211*2 θ . Then 
we prove several properties of the two power functions.  
5.5.1 One-stage power function ( )VnnP s ,,, 1211*1 θ  
 

































DT θ  for the hypothesis test in Equation (5.1) for Stage 1.  
Also recall previously defined random variable ( ) 211 2 SnX −= • . 
Since ( )VnnP s ,,, 1211*1 θ  is the joint probability of rejecting 0H  given ( )21* ,θθθ ∈  
and ( ) 201 2 SnX −≤ • , then we derive its exact function as: 
( ) ( ) ( )( )
( ) ( ) ( ) ( )
( ) ( )






















































































































































































































Using the fact that  
2V
X




ND σθ , this last expression is the 
expectation over X of a conditional probability given X, which is expressed simply in 




























































































where ( )1ναt  is the 1-α quantile of the t-distribution with 212111 −+= nnν degrees 
of freedom, )(⋅Φ  is the standard normal cumulative distribution function (cdf), ( )⋅I  is 






































































































































































 and 212111 −+= nnν . 
5.5.2 Two-stage power function ( )upVnnP s ,,,,, 01211*2 θ   
 




















ˆ θ  and 






































where ( ) 211 2 SnX −= • . 
Since ( )Xn •2  is a random variable, a function of X  in Equation (5.4), then 


















ExXDE  and 









































Since ( )upVnnP s ,,,,, 01211*2 θ  is the joint probability of rejecting 0H  given 
( )21* ,θθθ ∈  and 201SX ν> , then we derive its exact function as: 
( ) ( )( )
( ) ( ) ( ) ( ) ( ) ( )










































































































































+ θθ ,  
we obtain  ( ) ( ) 1222122111




uS . So  
( )( )







































To simply the above equation, let 



























It is easily seen that 




















S . 22S is the variance of 2D̂  given X . Since 2V
X
 is distributed 
as ( )12 νχ  with degrees of freedom 212111 −+= nnν  and  conditional distribution of 
2V
Y
 given X, is ( )22 νχ  with degrees of freedom 222212 −+= nnν , we can shorten 
the power expression for the true mean difference of the test product and the 
reference product ( *θ ) as the following  
( )











































































































































Since ( )( ) ( ) XXcXnnY −−+≤ •• 2221 4 , it is obvious that ( )( ) ( ) xxcxnn −−+ •• 2221 4  is 
the upper integration limit for the inner integral with respect to y. For ease of use, we 
let ( ) ( )( ) ( ) xxcxnnxaa −−+== •• 2221 4 . Since ( ) 201 2 SnX −≥ •  on the event whose 
probability is calculated in the integral, the lower limit of the integration in x is 

























































.   
If ( ) ( ) ( ) 222221 xnxnxn •== , then ( )xc3 = ( )( ) ( )( )4
1
2121 −++ •••• xnnxnn
 and 





.   
5.5.3 Properties of exact power functions 
The exact power functions ( )VnnP s ,,, 121121 θ  and ( )upVnnP s ,,,,, 01211*2 θ  are calculated 
by Equation (5.3) and Equation (5.5), respectively. )(xa , b, )(2 xc , )(3 xc , and )(4 xc are 
calculated by Equation (5.6), Equation (5.7), Equation (5.8), Equation (5.9), and Equation 
(5.10), respectively. Clearly, all of them except b depend on x, not V, while b does not depend 
on either x or V. 
Before we develop the numerical method of obtaining the critical value, we will prove 
several properties of ( )VnnP s ,,, 121121 θ  and ( )upVnnP s ,,,,, 01211*2 θ . 





∫= ,)( . If both ( )bf  and ( )bxg , are non-increasing 
continuous functions of b , then )(bH is a monotonically non-increasing continuous function 
of b for a nonnegative ( )bxg , and ( ) cbf ≥  ( c is a constant).  





∫= ,)( , then )(bH  is a definite integral where both the limits 













∂+′=′ ,,)( . 





, ( ) 0, ≥bxg , and ( ) cbf ≥ . 
Proposition 1: ( ) ( )upVnnPupVnnP ss ,,,,,,,,,, 01211*20121122 θθ ≥  for any 2* θθ ≥  or 
1
* θθ ≤ .  


















































































.   
Φ  is monotonically increasing with derivative increasing on the negative axis, and  
the difference of two normal distribution function values given in the integrand of 




















, and 12 KK >  does not involve 
*θ . 
Since the derivative of ( )kz −Φ  with respect to z  is positive and increasing for 
0<− kz , it follows immediately from the mean value theorem and chain rule that  





By Lemma 1, the decreasing property of the integrand with respect to *θ  gives the 
















1 ++−θθ 0≥  for 1
* θθ ≤ ,  then the 
derivative of ( )kz −Φ  with respect to z  is decreasing for 0>− kz , it follows 
immediately from the mean value theorem and chain rule [60] that  





By Lemma 1, the increasing property of the integrand with respect to *θ  gives the 
integral the same property. Therefore, we have proved that                                                                                           
( ) ( )upVnnPupVnnP ss ,,,,,,,,,, 01211*20121112 θθ ≥  for any 2* θθ ≥  or 1* θθ ≤ .  
Proposition 2: ( )VnnP s ,,, 121121 θ  is a decreasing function of V . 
Proof: Substituting 2
* θθ =  in Equation (5.3) and by change of variable, we have 













































































































 and 212111 −+= nnν . 
Since 1c is a constant, free of V, then it is easily seen that 
2
1 Vc  is a decreasing 









, then the integrand is 




Since both the upper integration and integrand bounded between 0 and 1 in the 
right side of Equation (5.11) are a monotonically decreasing function of V and 01 >c , 
which satisfy all conditions in Lemma 1, then ( )VnnP s ,,, 121121 θ  is a monotonically 
decreasing function of V. 
Proposition 3: ( )VnnP ,,, 2121 θ  is a decreasing function of V. 
Proof: As we discussed in Chapter 4, ( )VnnP ,,, 21*1 θ  is the probability of rejecting 
the null for the two one-sided tests procedure for the crossover bioequivalence study. 
Plugging 2






















































































































is a monotonically decreasing function of V.  




Both the integrand, which is bounded between 0 and 1, and the upper integration 
limit are decreasing continuous functions of V and 00 >c , so from Lemma 1, we know 
that ( )VnnP ,,, 2121 θ  is a non-increasing function of V. 
Proposition 4: For fixed upnn  and,,,, 012112θ , there exists a maximum of 
( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  on { }0≥V . 
Proof: Recall ( )xn •2 is a real valued quantity defined by Equation (5.4) rather than 
an integer, and so it is a continuous function of x.  Substituting 2
* θθ =  in Equation 












































































.               (5.13) 
Since ( ) ( )( ) ( ) xxcxnnxaa −−+== •• 2221 4 and ( ) 201 2 Snb −= • , both are free of V. 
From the above equation, ( )upVnnP s ,,,,, 0121122 θ is always a nonnegative continuous 
function of V for any V≥0. Similarly, from Equation (5.11), ( )VnnP s ,,, 121121 θ  is always 
a nonnegative continuous function of V for any V≥0. 
( ) 0,,,,, 0121122 →upVnnP s θ  as 0→V since both ( )⋅Φ  values in the integrand of 
























 in the integrand of right side in Equation (5.11) 
goes to 0. Therefore, ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ α→  as 0→V . 
( ) 0,,,,, 0121122 →upVnnP s θ  as ∞→V  since both ( )⋅Φ  values in the integrand of 




































 in the integrand of right side 
in Equation (5.11). Therefore, ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ 0→  as 
∞→V .  
 We can find 0>δ  such that 
[ ] [ ]







[ ]δδ 1,∈l and then the maximum of the continuous function ( ) ( )uVPVP ss ,21 +  exists 
on [ ]δδ 1, . 
Let N be the upper bound for the sample size of n . In Proposition 5, we will bound 
the any solution of n of Equation (5.4) is less than or equal to N. 
Proposition 5: If N is greater than or equal to 











νθ αα , then any solution of n of 




























































νθθ , where 


















−= , ( )Xnnn •• += 21  and 2−= nν . 
Proof: Let ( )νX  denote a random variable as 2νχ , then the right-hand side 
expression of the formula we will equate to 0p  is  


















































2       (5.14) 
The proof goes in three steps: 
(1) For 31≥ν , ( )( ) 3103 −<≥ ννXP  which follows from the Markov-
Cheybchev inequality and the moment generating function of chi-square, 
since ( )( ) ( )( )( )( ) ( )( )( ) ( )ννννν 3.0exp7log5.07/9exp37/3exp3 −<−−=−<≥ XEXP . 
Taking 31≥ν  gives the right-hand side< 410− . 
(2) When 33≥ν , so that 31≥ν , also ( ) ( )31αα ν tt ≤ , and the integrand in 
curly brackets in (5.14) is positive for all ν3≤X  as long as 
( ) 1/3 Snt θνα <  
which holds as long as ( )( )2213 νθ αtSn ≥ .  
(3) Finally, by removing an event of probability at most 410−  from the 




positive with 3/ ≤νX  on the complement, which means that (5.14) is 




















24 , which is  0p>  as 











−Φ −νθ α . Proof is over. 
Let bV  be the lower bound of the search range for V. bV  is obtained from the 
following inequality: ( )1522201 ,101/ νχν −−≥ qVS b , where ( )152 ,101 νχ −−q  is the 
quantile of ( )12 101 5 νχ −− . Let eV  be the upper bound of the search range for V. In 
Proposition 6, eV  is chosen so large that the RHS of the following inequality < 
4510.0 − . ( ) ( )
[ ]






s θθννχννν −+<≤≥≤ ∈ . 
In Proposition 6, the lower bound bV  and upper bound eV  for the search range of V 
can be determined by satisfying the above conditions.  
Proposition 6: We find that ( )VnnP s ,,, 121121 θ  + ( ) αθ <upVnnP s ,,,,, 0121122  
whenever bVV <  or eVV > .   
Proof: Let ( ) 2111 SX νν = . 
Step (1) is to recall 
sP1  is decreasing in V and by the Intersection-Union Test size 
inequality of Berger and Casella [50] (see Theorem 8.3.24 on Page 396 in Section 
8.3.3), ( ) αθ <> 0,,, 1211*1 VnnP s . 




( ) ( ) ( )( )220121012 //, VSVXPSSPuVP s νν ≥=≥≤  
( )uVP s ,2  goes to 0 when 0→V . Therefore, with ( )1522201 ,101/ νχν −−≥ qVS b , we 
find that ( )VnnP s ,,, 121121 θ + ( ) αθ <upVnnP s ,,,,, 0121122  whenever bVV < .  
Step (3) is to note that for large V, ( ) ( ) 0011 →<≤ SSPVP s  (and express this 
probability in terms of 2
1νχ  quantiles as ( )122012 ,/ ννχ VSp ), where ( )122012 ,/ ννχ VSp  
is the probability of 2201
2 /  toequalor an smaller th 
1
VSνχν . 
Step (4) is to note that for fixed u and ∞→V , 
( ) ( )( ) ( )( )22212 /4/4 VXVXa νθθνν −−+=  and ( ) ( )0)(,2 ≥≤ XaPuVP s . This goes to 0 
because ν does not depend on V and according to Prop.5 is bounded above by N, 
while ( ) 2/VX ν  is 2νχ  distributed. In particular, 
( ) ( )
[ ]






s θθννχννν −+<≤≥≤ ∈  
and eV  is chosen so large that the RHS < 
4510.0 − . Therefore 
( )VnnP s ,,, 121121 θ + ( ) αθ <upVnnP s ,,,,, 0121122  whenever eVV > . 
Remark 1: In Proposition 6, we established the search range { }eb VVVV ≤≤:  for 
V. Here we determine the search range for positive u for *21T . The positive lower 
bound for u  is αZ  since our calculation indicates that 
( )VnnP s ,,, 121121 θ + ( ) αθ >upVnnP s ,,,,, 0121122  for some V when αZu = . 

















































































                    (5.15). 
It is easy to see that the first partial derivative of ( )upVnnP s ,,,,, 0121122 θ  with 
respect to u is positive since ( ) 03 >xc  and ( ) 04 >xc . Therefore, 
( )upVnnP s ,,,,, 0121122 θ  is a decreasing function of positive u  for a given positive V. 
When ∞→u , ( ) 1,,,,, 0121122 −→upVnnP s θ  uniformly for all positive V. Hence 
0u∃  such that ( )VnnP s ,,, 121121 θ + ( ) αθ <00121122 ,,,,, upVnnP s for all positive V .   
Let [ ] [ ]0 , , uZVV eb α×=Β . Β is a compact set. By intermediate value theorem [60], 
the exact critical value, αu , is derived as the largest value of u for which  the 
condition: ( ) ( )[ ] αθθ α ≤+ upVnnPVnnP ss
V
,,,,,,,,max 0121122121121  holds.  
5.6 Numerical analysis 
 
The type I error rate for our proposed sample re-estimation procedure is 
( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ  since the maximum of the probability of 
rejecting 0H  under 0H in the hypothesis (5.1) occurs at the boundary 2θ  or 1θ  (see 
Proposition 1). 
Section 5.6.1 summarizes the overall method for obtaining the largest u such that 
( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  is exact α. We denote this u as αu . Section 5.6.2 




of ( )VnnP s ,,, 121121 θ  and ( )upVnnP s ,,,,, 0121122 θ . Section 5.6.3 summarizes all numerical 
errors including the numerical approximation error bounds for the integrals at a fixed 
V and the upper bound for the difference between two adjacent grid points such as 
[ ]1, +kk VV , k=1,.2, …. Section 5.6.4 presents an example for comparing the numerical 
value for ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  for u at two values. 
5.6.1 Numerical method for obtaining critical values 
 
The first part of this section provides the conceptual reasoning to prove there exists 
a global maximum of ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  in the range 
{ }eb VVVV ≤≤:  for V.  
The second part of this section provides the computational method for obtaining 
αu  as the largest u such that ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  takes a value as 
large as α  for some V within the interval { }eb VVVV ≤≤: . 
Due to the complexity of the analytical expression for the second derivative with 
respect to V of ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ , it is impossible to derive its 
maximum in the bounded range { }eb VVVV ≤≤: . However, the existence of this 
maximum in a bounded interval of V can be reasonably assumed since ( )01 SSP >  
approaches 1 for any unusually large V. As ( ) 101 →> SSP , the influence of the Stage 
1 data is not significantly important and the two-stage study can be approximately 
treated as the fixed sample study. Therefore, ( )upVnnP s ,,,,, 0121122 θ  is a decreasing 




for any V>0 (see Proposition 3). We also know that ( )VnnP s ,,, 121121 θ  is a 
monotonically decreasing function of V for any V>0 (see Proposition 2). Hence 
( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  is a decreasing function of V for large 
positive V.  From Proposition 4, we know that there exists a maximum for 
( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  for any V>0. By carefully choosing the search 
range [ ]eb VV ,  for V and αZu ≥  for u (see Proposition 6 and Remark 1), respectively, 
we can assure that there exists a maximum in the bounded interval [ ]eb VV ,  and this 
maximum is the global maximum for any V>0 based on the calculation.   
The algorithm to obtain αu  is described in the following steps. We calculate the 
21n  and 22n  from Equation (5.4), which is bounded by N (see Proposition 5) and 
obtain the maximum of ( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ  for a fixed u  in the 
bounded interval [ ]eb VV , . We use αZ  as the initial value for u. If the maximum of 
( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ  is greater than α , we increase u by 0.001. We 
continue this iteration until the difference between α  and the maximum of 
( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 01211*2 θ  is less than or equal to 410− .  The last u is 
αu . 
For a fixed u, we use a grid search to obtain the maximum of ( )VnnP s ,,, 121121 θ  + 
( )upVnnP s ,,,,, 0121122 θ  among the grid points in the bounded interval [ ]eb VV , . The 
numerical value for ( )VnnP s ,,, 121121 θ  and ( )upVnnP s ,,,,, 0121122 θ  at a given V can be 




The critical value for the two-stage study, αu , is determined as the largest u such 
that ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  takes a value as large as α  for some V 
within the interval { }eb VVVV ≤≤: . Error bounds for numerical approximation of 
( )VnnP s ,,, 121121 θ  and ( )upVnnP s ,,,,, 0121122 θ  can be obtained in Section 5.6.3.1. The 
maximum difference between two adjacent grid points can be quantified in Section 
5.6.3.2. 
5.6.2 Numerical calculation of ( )VnnP s ,,, 1211*1 θ  and ( )upVnnP s ,,,,, 01211*2 θ  
 
For a fixed critical value u, we use a grid search in the bounded interval [ ]eb VV ,  to 
obtain the maximum of ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ . We divide the interval 
[ ]eb VV ,  into many subintervals of length 310−  or 410− . The typical interval [ ]eb VV ,  for 
)( 1211 nn = less than 30 is [ ]7.0 ,1.0   





dxxf  (see 





dxxf  is calculated by Equation (5.17) 
which is derived from Simpson’s rule. In Simpson’s Rule we approximate the 
function ( )xf *  as a quadratic in each interval and require that the quadratic agree 
with three of the points from each subinterval.  





































dxdyyxf 7105 −⋅≤ , where 
( )212999999.02* −= •nVb χ . Now we need to compute a two dimensional definite integral. 
To ensure a good approximation for the entire integral, we have to approximate the 
inner integral first and then use a second approximation to deal with the outer 




,  by ( )xI1ˆ  (see Equation 






dxxI by Equation (5.24) with the trapezoidal rule. 
 
5.6.3 Numerical approximation errors 
 
This section mainly discusses all levels of numerical errors. The first subsection 
discusses the numerical approximation error bounds for the integral at a fixed V and 
the second subsection numerically quantifies the maximum difference between two 
adjacent grid points using monotone functions in the integrand for any interval 
[ ]1, +kk VV , k=1,.2, … , in the neighborhood of *V  at which the maximum of 
( ) ( )αθθ upVnnPVnnP ss ,,,,,,,, 0*121122*121121 +  occurs. 
5.6.3.1 Numerical approximation error bounds for the integrals at a fixed V  
 




The numerical approximation error bound, ( )*1 fR SPS  [61] (see Equation (5.18)), in 


















ξ , which is the analytical and uniform upper bound 
in x on the bounded interval [ ]1 ,0 c  for the fourth derivative with respect to x of ( )xf *  
(see Appendix 5.2 for more detail).  
2. Error bounds for the numerical approximation of ( )upVnnP s ,,,,, 0121122 θ  
When calculating the numerical value of ( )upVnnP s ,,,,, 0121122 θ , the first numerical 
error is the difference between the definite integral and an improper integral. This 
difference is 7105 −⋅ . The numerical approximation error bound, ( )fxR innerS ,  (see 




, , is an analytical 













ξ , which is the analytical 
and uniform upper bound in y on the bounded interval [ ]a ,0  for the fourth derivative 
with respect to y of ( )yxf , (see Appendix 5.3 for more detail).  







S dxfxR  is approximated by 3Î  (see Equation (5.22)) using the trapezoidal 










S dxfxR , is approximate since we bound 
( )( )( )fxRdxd innerS ,22  by the upper bound of second finite differences of the integrand 
values ( )fxR innerS ,  at the grid points ( 410 ) for the trapezoidal rule.  This is necessary 
because we can’t analytically bound ( )( )( )fxRdxd innerS ,22  on the bounded interval 
[ ]*bb  , . 
The numerical approximation error bound, ( )( )ς1ÎRouterS  (see Equation (5.25)), for 






dxxI , is approximate since we bound 
( )( )xIdxd 122 ˆ  by the upper bound of second finite differences of the integrand values 
1Î  at up to 
410 breakpoints for the trapezoidal rule.  As above, we cannot analytically 
bound ( )( )xIdxd 122 ˆ  on the bounded interval [ ]*bb  , .  
5.6.3.2 Maximum difference between two adjacent grid points  
 
Although one can refine the grid, one cannot arrive at any mathematically provable 
bound on the trapezoid-rule errors.  We quantify the bound on ( )VnnP s ,,, 121121 θ  
+ ( )upVnnP s ,,,,, 0121122 θ  between grid-points in V so that we can check the smoothness 




From Equation (5.9), the upper bound for ( )VnnPs ,,, 121121 θ  in the bounded interval 
[ ]1, +kk VV  can be calculated by 1bP .  















































































ν .  
By choosing a large number of grid points, the upper bound between 1bP  and 
( )ks VnnP 121121 ,,θ  for any interval [ ]1, +kk VV , k=1,.2, … , in the neighborhood of *V  at 
which the maximum of ( ) ( )αθθ upVnnPVnnP ss ,,,,,,,, 0*121122*121121 +  occurs is 510−   
From Equation (5.19), we approximate the upper bound for ( )αθ upVnnP s ,,,,, 0121122  
in the bounded interval [ ]1, +kk VV  by 2BP . 
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By choosing a large number of grid points, the maximum difference between 1bP  
+ 2BP and ( )ks VnnP 121121 ,,θ  + ( )αθ upVnnP ks ,,,,, 0121122  for any interval [ ]1, +kk VV , k=1,.2, … , 
in the neighborhood of *V  at which the maximum of ( )*121121 ,,, VnnP s θ  + 
( )αθ upVnnP s ,,,,, 0*121122  occurs is 410−   
5.6.3.3 A numerical example   
 
We present an example for illustrating the levels of all error bounds. Using 
Simpson’s rule with 5,000 intermediate points, for the parameter values 




parameter values ( ) ( )782.1,275.0,10,10),25.1log(,,,, 12112 =uVnnθ , the difference between 
the definite integral and an improper integral for ( )upVnnP s ,,,,, 0121122 θ  is 
7105 −⋅ . 
( )( )ς1ÎRouterS  and ( )( )ζ3ÎR  from the trapezoidal method with 5,000 intermediate points 
are, respectively, 41087.1 −⋅  and 91060.1 −⋅ . 3Î  is 
71020.1 −⋅ . Let SPSR 2 be the total error 
for ( )upVnnP s ,,,,, 0121122 θ . S
P
SR
2 = 7105 −⋅ + 41087.1 −⋅ + 91060.1 −⋅ + 71020.1 −⋅ = 41087.1 −⋅ .  
Hence the total integration error of ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 01211*2 θ  for 
V=0.275 is 161022.2 −⋅ + 41087.1 −⋅ = 41087.1 −⋅ . 1bP  + 2BP  in which V is within the 
interval [0.2750, 0.2751] is 0.05010652 while the numerical value of ( )VnnP s ,,, 121121 θ  
+ ( )upVnnP s ,,,,, 0121122 θ  is 0.04974823 for the parameter values 
( ) ( )782.1,275.0,10,10),25.1log(,,,, 12112 =uVnnθ . The upper bound for the difference 
between 1bP  + 2BP  and ( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ  is 4106.3 −⋅ . So the 
upper bound for ( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ  is 0.0503. 
5.6.4 An example for comparing ( )VnnP s ,,, 121121 θ + ( )upVnnP s ,,,,, 0121122 θ  with 
respect to V for two different u values  
 
We present one example to show the behavior of 
( ) ( )upVnnPVnnP ss ,,,,,,,, 0121122121121 θθ + , with respect to V for two different u values 
when 11n = 12n =10 in Figure 5.1. In Figure 5.1, we use ( )1805.0t  as the value of u for 
the dot line and use αu  as the critical value of u for the solid line. It is clearly shown 




u=1.782, the type I error rate does not exceed 0.05. The type I error rate becomes 
larger if ( )ν05.0t  is used for 18>ν  when more subjects are added in the second stage. 
Figure 5.1 Experimentwise type I error rate, ( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ , against V 









Some statistical power for analyzing the combined data of Stage 1 and Stage 2 can 
be lost since the degrees of freedom for 22T are 221 −+ •• nn  and the degrees of 
freedom for *22T  are 421 −+ •• nn . In order to evaluate how much power may be lost, 
we will evaluate the difference in the null distributions of 22T  and 
*
22T , and the 






Comparing 2S  and ( )2*S , we can easily see that the difference between 22T and 
*
22T is that the contribution from the difference of the averaged period differences for 
each sequence between Stage 1 and Stage 2 is omitted in *22T . Let dP be the 
difference in period effect between Period 2 and Period 1. It is reasonable to assume 
that dP is the same for both stages since they belong to the same study.  




To evaluate the null distributions of 22T  and 
*
22T , we use the following simulation 
schemes assuming that )25.1log(* =θ  and 05.0=dP : 
1) Simulate kd11 , k=1,2…,n11, from a normal distribution with ( ) dPdE k += *11 θ  and 
( ) 211 VdV k = , and kd12 , k=1,2…,n12, from a normal distribution with  
( ) dPdE k +−= *12 θ  and ( ) 212 VdV k = . 
2) Compute 21S  from Stage 1 data generated in Step 1. 
3) Calculate the new total sample size ( •• + 21 nn ) from the power function (5.4) 
assuming that 9.00 =p , ( ) 05.0 ,25.1log 0* == θθ  and 21S  is used as 2V  if 21S > 20S . 
If 02 =n , then stop here. Otherwise continue to next step. 
4) Simulate kd21  (the difference in Y between Period 2 and Period 1 for the k
th subject 
in Sequence 1 at Stage 2), k=1,2…, 21n , from a normal distribution with 
( ) dPdE k += *21 θ  , and ( ) 221 VdV k = , and kd22  (the difference in Y between Period 2 




distribution with  ( ) dPdE k +−= *22 θ  and ( ) 222 VdV k = . Note that 
( ) 112121 2/ nnnn −+= ••  and ( ) 122122 2/ nnnn −+= •• . 
5) Compute *S , S , 22T , and
*
22T . 
6) Repeat Steps 1 to 5 many times, for example 50,000 times.  
The null distributions of T22 and 
*
22T  under different parameters are compared in 
Tables 5.1 and 5.2. From these two tables, we can see that the quantiles of the null 
distributions of T22 and 
*
22T  match at the first decimal except for extreme quantiles 
and those quantiles become larger with smaller •1n  under the same other parameters. 
Comparing Table 5.1 and Table 5.2, we can see that the quantiles of the null 
distributions of T22 and 
*
22T  become larger with larger 






Table 5.1 Comparison of the null distributions under )25.1log(* =θ  and 05.0=dP  between 
22T and 
*
22T  when 2563.00 =S  ( 101211 == nn ) 
 V  
0.25 0.3 0.4 0.45 0.5 
22T  
*
22T  22T  
*
22T  22T  
*
22T  22T  
*
22T  22T  
*
22T  
0.1% -2.810 -2.721 -3.222 -3.180 -3.426 -3.432 -3.435 -3.415 -3.118 -3.117 
0.5% -2.338 -2.238 -2.627 -2.582 -2.797 -2.785 -2.781 -2.781 -2.689 -2.693 
1% -2.107 -2.025 -2.366 -2.322 -2.507 -2.501 -2.471 -2.477 -2.446 -2.445 
2% -1.860 -1.799 -2.060 -2.024 -2.184 -2.174 -2.163 -2.163 -2.141 -2.143 
5% -1.469 -1.434 -1.637 -1.606 -1.717 -1.714 -1.703 -1.699 -1.731 -1.734 
10% -1.147 -1.115 -1.266 -1.239 -1.327 -1.331 -1.332 -1.335 -1.335 -1.337 
50% -0.002 0.000 0.011 0.008 0.000 0.000 0.001 0.001 0.002 0.002 
90% 1.171 1.149 1.290 1.262 1.334 1.331 1.327 1.334 1.329 1.332 
95% 1.493 1.467 1.659 1.627 1.701 1.704 1.718 1.720 1.717 1.714 
98% 1.897 1.854 2.098 2.051 2.118 2.109 2.166 2.169 2.146 2.152 
99% 2.142 2.083 2.374 2.309 2.414 2.408 2.477 2.479 2.443 2.452 
99.5% 2.378 2.323 2.625 2.557 2.721 2.741 2.758 2.765 2.703 2.712 













Table 5.2 Comparison of the null distributions under )25.1log(* =θ  and 05.0=dP  between 22T  
and 
*




0.3 0.4 0.5 0.52 
22T  
*
22T  22T  
*
22T  22T  
*
22T  22T  
*
22T  
0.1% -2.473 -2.394 -3.037 -3.058 -3.286 -3.269 -3.252 -3.235 
0.5% -2.066 -2.040 -2.537 -2.503 -2.722 -2.697 -2.702 -2.697 
1% -1.843 -1.781 -2.301 -2.286 -2.443 -2.428 -2.379 -2.379 
2% -1.649 -1.607 -2.022 -1.989 -2.119 -2.128 -2.146 -2.139 
5% -1.329 -1.294 -1.612 -1.589 -1.685 -1.685 -1.684 -1.682 
10% -1.028 -1.006 -1.252 -1.232 -1.302 -1.301 -1.312 -1.312 
50% -0.010 -0.009 0.003 0.008 -0.005 -0.005 -0.002 -0.002 
90% 1.013 1.006 1.229 1.210 1.317 1.317 1.311 1.313 
95% 1.285 1.272 1.621 1.610 1.697 1.695 1.688 1.686 
98% 1.616 1.580 1.993 1.970 2.111 2.116 2.122 2.133 
99% 1.851 1.777 2.264 2.233 2.408 2.399 2.403 2.410 
99.5% 2.017 1.958 2.495 2.460 2.723 2.731 2.715 2.718 
99.9% 2.424 2.414 2.911 2.878 3.353 3.346 3.261 3.273 




To evaluate the alternative distributions of 22T and
*
22T , we use the same simulation 
schemes in Section 5.7.1 but assume that 05.0* =θ  and 05.0=dP . The results in 
Tables 5.3 and 5.4 indicate that the quantiles of the alternative distributions of T22 and 
*
22T match at the first decimal except for 0.1% or 99.9% quantile and those quantiles 
become larger with smaller •1n  under same other parameters. Comparing Table 5.3 
and Table 5.4, we can see that the quantiles of the alternative distributions of T22 and 
*
22T  become larger with larger 




Table 5.3 Comparison of the alternative distributions under 05.0* =θ  and 05.0=dP  between 22T  
and 
*
22T  when 2563.00 =S  ( 101211 == nn ) 
  V 
0.25 0.3 0.4 0.45 0.5 
22T  
*
22T  22T  
*
22T  22T  
*
22T  22T  
*
22T  22T  
*
22T  
0.1% -6.211 -6.044 -6.408 -6.318 -6.715 -6.685 -6.725 -6.695 -6.627 -6.637 
0.5% -5.629 -5.627 -5.874 -5.790 -5.978 -5.982 -5.933 -5.977 -5.952 -5.936 
1% -5.379 -5.317 -5.610 -5.548 -5.666 -5.690 -5.648 -5.648 -5.650 -5.659 
2% -5.126 -5.065 -5.292 -5.254 -5.340 -5.370 -5.299 -5.306 -5.292 -5.304 
5% -4.736 -4.682 -4.861 -4.842 -4.868 -4.875 -4.828 -4.833 -4.821 -4.834 
10% -4.382 -4.347 -4.471 -4.445 -4.467 -4.478 -4.433 -4.446 -4.401 -4.404 
50% -3.190 -3.189 -3.145 -3.147 -3.056 -3.068 -3.010 -3.018 -2.993 -3.000 
90% -2.012 -2.069 -1.842 -1.866 -1.654 -1.671 -1.605 -1.612 -1.598 -1.598 
95% -1.674 -1.749 -1.474 -1.511 -1.255 -1.279 -1.213 -1.219 -1.189 -1.197 
98% -1.296 -1.355 -1.047 -1.098 -0.774 -0.791 -0.737 -0.747 -0.733 -0.743 
99% -1.071 -1.122 -0.772 -0.815 -0.454 -0.481 -0.415 -0.422 -0.450 -0.455 
99.5% -0.870 -0.923 -0.495 -0.549 -0.175 -0.183 -0.169 -0.172 -0.157 -0.155 




















Table 5.4 Comparison of the alternative distributions under 05.0* =θ  and 05.0=dP  between 22T  
and 
*




0.3 0.4 0.5 0.52 
22T  
*
22T  22T  
*
22T  22T  
*
22T  22T  
*
22T  
0.1% -5.648 -5.601 -6.091 -6.001 -6.383 -6.345 -6.283 -6.288 
0.5% -5.236 -5.231 -5.644 -5.586 -5.755 -5.784 -5.707 -5.730 
1% -4.994 -4.990 -5.422 -5.370 -5.545 -5.543 -5.455 -5.468 
2% -4.754 -4.733 -5.150 -5.102 -5.206 -5.208 -5.157 -5.165 
5% -4.406 -4.385 -4.705 -4.671 -4.748 -4.752 -4.736 -4.732 
10% -4.110 -4.090 -4.320 -4.308 -4.360 -4.361 -4.348 -4.345 
50% -3.073 -3.070 -3.042 -3.050 -3.013 -3.013 -2.992 -2.994 
90% -2.055 -2.074 -1.773 -1.790 -1.660 -1.663 -1.646 -1.643 
95% -1.761 -1.781 -1.422 -1.439 -1.275 -1.276 -1.238 -1.238 
98% -1.414 -1.449 -1.015 -1.032 -0.826 -0.830 -0.823 -0.822 
99% -1.203 -1.233 -0.721 -0.745 -0.507 -0.507 -0.537 -0.536 
99.5% -0.981 -1.034 -0.477 -0.493 -0.292 -0.292 -0.272 -0.274 
99.9% -0.546 -0.672 0.051 -0.007 0.186 0.185 0.350 0.351 
5.8 Discussion and conclusions 
 
Our simulations show that the null distributions of 22T  and 
*
22T  are close to each 
other and the alternative distributions of 22T  and 
*
22T  are also close to each other. Our 
simulations also show that the powers using ( )2221,TT  and ( )*22*21,TT  are matched at the 
second digit for all cases and the type I error rates using ( )2221,TT  and ( )*22*21,TT  are 
matched at the second digit for most of cases. Hence we do not lose much 
information if the simplified test statistics ( )*22*21,TT  is used instead of ( )2221,TT . 




study. Otherwise, the exact critical value αu  for 
*
21T  (or - αu  for 
*
22T ) is used for two-
stage study. We calculate ( )VnnP s ,,, 121121 θ  and ( )upVnnP s ,,,,, 0121122 θ  for any given 
V and u with the numerical integration methods. The sum of all calculated levels of 
numerical error bounds at grid points and between grid points is about 10-4. We find 
the bounded interval for V. 
To search for αu , we use the following strategy. The initial value for u is αZ . If 
the maximum of ( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ  in the bounded interval [ ]eb VV ,  
is greater than α , we increase u by 0.001. We continue this iteration until the 
difference between α  and the maximum of ( )VnnPs ,,, 121121 θ + ( )upVnnP s ,,,,, 01211*2 θ  is 
less than or equal to 410− . Due to all levels of errors, we can make α =0.0495. 
 
Appendix 5.1 Details for Numerical integration method 
 
1. Numerical method for calculation of ( )VnnP s ,,, 121121 θ  and its accuracy 
From Equation (5.11), we know ( )VnnP s ,,, 121121 θ  is calculated by one-dimension 
integration. Now we use the Simpson’s rule to obtain the numerical value for 


















































































Let ( )*1 fR SPS  denote the numerical error for the integration. Î  is the numerical 
estimate for I . 
In the Simpson’s rule, we divide the inner interval [ ]1,0 c  into the even number ( 1n ) 





dxxfI = Î + ( )*1 fR SPS , where   






























ˆ ,                  (5.17) 





















ξ ,                                                                (5.18) 
Here 00 =x , 1*hixi =  1,...,2,1 ni =∀ . ( )*1 fR SPS  calculated by (5.18) is an analytical 













which is the analytical and uniform upper bound in x on the bounded interval [ ]1 ,0 c  











ξ  will be derived 






2. Numerical method for calculation of ( )upVnnP s ,,,,, 0121122 θ  and its accuracy 
In this section, we will discuss the Simpson’s rule to obtain the numerical value for 








0121122 ),(,,,,,θ .        (5.19) 
Here, 


























































Since the above integration is an improper integration, then the relative large upper 
integration limit (denoted by *b ) in the above outer integration can be determined 

























. After *b is determined, we 
can use the Simpson’s rule for obtaining the numerical value for ( )upVnnP s ,,,,, 0121122 θ  

























































































































































































Let impR  be the upper bound for difference between the improper integration and 
the finite integration with upper limit *b . Then impR  is less than or equal to 7105 −⋅ .  









dxxII . Let ( )fxR innerS ,  denote the 
numerical error for the inner integration. ( )xI1ˆ  is the numerical estimate for ( )xI1 . 
In the Simpson’s rule, we divide the inner interval [0, a] into the even number (n) 




1 , = ( )xI1ˆ + ( )fxR innerS , , where   


























1201 ,     (5.20) 

















ξ ,                                                          (5.21) 




The numerical approximation error bound, ( )fxR innerS ,  is an analytical upper bound 













ξ , which is the analytical and uniform 
upper bound in y on the bounded interval [ ]a ,0  for the fourth derivative with respect 












ξ  will be derived in Appendix 5.3.  






S dxfxRI  by 3Î  using the trapezoidal rule. In the 
trapezoidal rule, we divide the outer interval [ ]*,bb  into the number (n*) steps of 






S dxfxRI = ( )xI3ˆ + ( )( )ζ3ÎR , where  

























S fxRfxRfxRhI ,      (5.22) 














ς ,                                             (5.23) 
00 =x , 
**hixi =  










ς is bounded numerical 
second-order derivative. 
Let ( )( )ς1ÎRouterS  denote the numerical error for the outer integration of 1Î . 2Î  is the 




In the trapezoidal rule, we divide the outer interval [ ]*,bb  into the number (n*) 

















S dxfxR , where  























xIxIxIhdxxI + ( )( )ς1ÎRouterS ,                   (5.24) 














ς ,                                                                  
(5.25) 
00 =x , 
**hixi =  











ς is bounded numerical 
second-order derivative. 
( )( )ζ3ÎR  and ( )( )ς1ÎRouterS  are approximate bounds depending on the numerical 






S dxfxR  is the numerical 
integral of the exact analytical bound for the inner integral. 
Let SPSR
2 be the total integration error in calculation of ( )upVnnP s ,,,,, 0121122 θ . Then 
SP
SR






S dxfxR + ( )( )ζ3ÎR . 
3. Numerical accuracy for  ( )VnnP s ,,, 121121 θ  + ( )upVnnP s ,,,,, 0121122 θ    
Let SR  be the total integration error in calculation of ( )VnnP s ,,, 121121 θ  and 






























































































. Then ( ) ( ) ( )xgxgxf 21* ⋅= . 
From the chain rule of differentiation, the fourth-order derivative of ( )xf *  with 
respect to x is written as 












































Clearly we have to obtain all up to fourth-order derivatives of both ( )xg1 and ( )xg2  
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 achieves the maximum value at 
( )( )12/72 12 −−= νVx , then ( )
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, and  























. Then ( ) ( ) ( )yxgyxgyxf ,,, 21 ⋅= . 
From the chain rule of differentiation, the partial fourth-order derivative of 
( )yxf , with respect to y is written as 
( ) ( ) ( ) ( ) ( ) ( ) ( )





































































Clearly we have to obtain all up to fourth-order partial derivatives of 
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 achieves the maximum value at 
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Chapter 6   Sensitivity analyses 
6.1 Introduction 
 
In the evaluation of a bioequivalence study, it is a common practice to assume that 
both log(AUC) and log(Cmax) are normal variables [1]. However the normality 
assumption of the log(Cmax) in a bioequivalence study cannot always be assumed 
due to the skewness based on the limited simulation results in Chapter 2. Our limited 
simulation scenarios in Chapter 2 show that the distribution of the log(AUC) can be 
heavy tailed.  
In this chapter, we compare the type I error rate, sample size, and power of two 
one-sided tests (TOST) we describe in Chapters 4 and 5 if the log(Cmax) (or 
log(AUC)) follows one of three non-normal distributions: heavy tailed t distribution, 
skew-normal distribution, or a mixture of two normal distributions, respectively, with 
the type I error rate, sample size, and power if the log(Cmax) (or log(AUC)) follows a 
normal distribution.  
In Section 6.2, we will briefly discuss three non-normal distributions: the skew-
normal distribution, t-distribution, and a mixture of two normal distributions. These 
three distributions closely mimic the empirical distributions from simulations based 
on the pharmacokinetic compartment models in Chapter 2. However, Chapter 2 only 
looked at a single time period and failed to account for the crossover design used in 
the bioequivalence setting. In Section 6.3, we simulate the response variable from the 
linear mixed effect model in Section 3.2. From the simulations, we look into the 




and power of TOST for the one stage study discussed in Chapter 4. In Section 6.4, we 
simulate the response variable from the linear mixed effect model in Section 5.2. 
Based on the simulations, we also look into the impact of non-normality of the 
response variable on the type I error rate and sample size for a two-stage study 
discussed in Chapter 5. 
6.2 Non-normal distributions 
 
In this section, we focus on three non-normal distributions: the skew-normal 
distribution, t-distribution, and a mixture of two normal distributions. The motivation 
for these three non-normal models is discussed in Chapter 2. Recall that ijkY denotes 
the response (log(AUC) or log(Cmax)) of the kth subject in the jth period of the ith 
sequence in the 2-period 2-treatment crossover study ∀ i=1, 2, j=1, 2 and k=1,.., ni. 
ijkY is modeled as ijkijjikijk FPSY εγ ++++= .  
From Chapter 3 to Chapter 5, we assume that ijkε denotes a random variable 
following a normal distribution with ( ) 0=ijkE ε , and ( ) 2TijkV σε =  if 2,1,, =∀≠ jiji  
for the test formulation and ( ) 2RijkV σε =  if 2,1,, =∀= jiji  for the reference 
formulation. We assume σσσ == RT  in two following sections. Let N(0,1) stand for 
the standard normal variable, then ( )1,0Nijk ⋅= σε . 
Now let us discuss three non-normal distributions. The first non-normal 
distribution is the t-distribution with ν  degrees of freedom denoted by ( )νt . The 
second non-normal distribution is the skew-normal distribution with the location 




which is denoted by ),1,0( ςSN . The expectation of ),1,0( ςSN  is 21//2 ςςπ + and 
the variance of ),1,0( ςSN  is ( )[ ]πςς 22 121 +− . We use the R package [62] for 
simulating skew-normal errors. In the following subsections, we respectively 
compare the type I error rate, power, and sample size if ijkε  follows ( )νσ t⋅  
or ),1,0( ςσ SN⋅  with the type I error rate, power, and sample size if ijkε  follows 
( )1,0N⋅σ .  
The third distribution in our simulation study is a mixture of two normal 
distributions. Assume that U is uniformly distributed in [0, 1], we write the mixture of 
2 normal variables as ( ) ( )22202110 , )(,)( σµδσµδ NUINUI ≤+⋅≥ . Here 
( )⋅I  is the indicator function, 0δ  is a constant in [0, 1], and ),( 2iiN σµ  denotes the 
normal variable with mean iµ  and variance 
2
iσ . 
We use this mixture model to investigate the impact of bimodality of the response 
distribution, in which a small fraction of the population (a subgroup) responds to a 
test formulation with a mean response 1µ  unequal to the mean response 2µ  of the 
majority of the population, on the type I error rate, power, and sample size. 
The subgroup’s variability 1σ  is also different from the variability of  the majority 






6.3 Impact of non-normality of the response variable on the type I error rate and 
power for the single stage study 
 
In this section, we simulate the within-subject difference in the response variable 
between the test and the reference from the linear mixed effect model in Section 3.2 
with non-normal distributed errors. Then we compare the type I error rate and power 
for the one stage study under non-normality than those under normality. 
6.3.1 Simulation scheme 
 
We use the following simulation scheme for evaluating the power under *θ  with 
the assumption of a true constant period effect which was assigned the fixed value of 
0.05 in order to conduct the simulations. In the context of a balanced cross over 
design, the value is arbitrary and will not impact the results of interest. To avoid 
specifying another parameter for random subject effect, we simulate the difference in 
the response variable for each subject in each sequence. Let ikd denote the difference 
in the response variable for Subject k between the period 2 and period 1 in Sequence i. 
So ( ) kikiiik PPd 1212*11 εεθ −+−+−= + ,  k=1,2…, in . 
1) Simulate ijkε from the non-normal distribution, e.g., ( )νσ t⋅ , ∀ i=1, 2, j=1, 2 and 
k=1,.., ni. 











































































−= θ . 
4) If ( )2211 −+≥ nntT α and ( )2212 −+≤ nntT α then pass=1. Otherwise pass=0. 
5) Repeat Steps 1 to 5 for 100,000 times.  
6) Calculate the percentage of rejecting 0H under 0H  in (3.1). 
6.3.2 Type I error rate and power in a one stage study 
 
In this subsection, we compare the simulated type I error rate and power for non-
normal distributions with those for normal distributions for the one stage study.  
The simulated type I error rate under )25.1log(* =θ and the simulated power 
under 05.0* =θ  in Tables 6.1 and 6.2, respectively if ijkε ~ ( )1,0N⋅σ , ( )νσ t⋅ , 
and ),1,0( ςσ SN⋅ . The simulation standard errors are less than 0.0005 when 106 Monte 
Carlo replications are used in Tables 6.1 to 6.4. Table 6.1 shows that the type I error 
rates under any of above three distributions for various sample size ( n ) are 
comparable to those under normality. From Table 6.2, we can see that the power 
values under ( )5t⋅σ  or ( )10t⋅σ  for various sample size are smaller than those under 
normality. But there is not much difference in power between the skew-normal and 





Table 6.1 Comparison of the simulated type I error rates (%) for various n values under 
)25.1log(* =θ , 05.012 =− PP , and 2.0=σ among ijkε ~ ( )1,0Nσ , ( )νσt , ( ) ( )νννσ t2− , 
and ( )ςσ ,1,0SN . 
     ijkε     
n            
( )1,0N⋅σ  ( )νσ t⋅  ( ) ( )νννσ t⋅− 2  ),1,0( ςσ SN⋅  
ν =5 ν =10 ν =5 1−=ς  5.0−=ς  5.0=ς  
20 4.99 4.87 4.96 4.94 4.97 5.01 5.01 
24 5.01 4.98 5.01 4.98 5.01 4.96 4.98 
28 5.00 4.99 5.00 4.99 4.98 5.02 4.97 
32 5.00 5.00 5.02 4.98 4.97 5.01 4.98 
36 4.93 4.98 4.98 4.99 5.02 5.01 5.01 
40 5.03 4.96 4.99 5.00 4.98 5.00 5.00 
 
Table 6.2 Comparison of the estimated power (%) from simulations for various n values under 
)25.1log(* =θ , 05.012 =− PP , and 2.0=σ  among ijkε ~ ( )1,0Nσ , ( )νσt , 
( ) ( )νννσ t2− , and ( )ςσ ,1,0SN . 
     ijkε              
n              
( )1,0N⋅σ  ( )νσ t⋅  ( )ν
ν
νσ t⋅− 2
 ),1,0( ςσ SN⋅  
ν =5 ν =10 ν =5 1−=ς  5.0−=ς  5.0=ς  
20 83.23 60.70 74.20 83.09 93.80 87.63 87.67 
24 89.45 70.40 82.12 89.00 96.94 92.80 92.76 
28 93.34 77.51 87.61 92.84 98.50 95.84 95.83 
32 95.86 82.73 91.41 95.32 99.30 97.59 97.60 
36 97.46 86.78 94.05 96.99 99.67 98.63 98.63 





The simulated type I error rate under )25.1log(* =θ and the simulated power 
under 05.0* =θ  are listed in Tables 6.3 and 6.4, respectively if 
ijkε ~ ( ) ( )21 ,03.0 )7.0(,07.0)7.0( σσ −≤+⋅≥ NUINUI .  
In Table 6.3, the subpopulation has a mean shift from the majority of the 
population, but the overall mean is log(1.25). Table 6.3 shows that the type I error 
rate is about 5.5%  when the within-subject difference in the response variable for the 
subpopulation is more variable than that for the majority of the population; the type I 
error rate is below 5% when the within-subject difference in the response variable for 
the subpopulation is less variable than for the majority of the population; the type I 
error rate jumps around 5% when the within-subject difference in the response 
variable for the subpopulation has the same variance as the majority of the 
population. Table 6.4 shows that the power is much smaller when one of two 
subpopulations has a larger variance than that under normality. This is because the 
overall variance for the mixture distribution with a more variable major population is 
much larger than the variance of the normal distribution. The power when two 








Table 6.3 Comparison of the simulated type I error rates (%) for various n values under 
)25.1log(* =θ , 05.012 =− PP , and 2.0=σ  when ijkε  ~ 
( ) ( )21 ,03.0 )7.0(,07.0)7.0( σσ −≤+⋅≥ NUINUI .  
n σσσσ == 21 ,2  σσσ == 21  σσσσ 2, 21 ==  
20 5.44 4.98 3.42 
24 5.51 5.04 4.09 
28 5.50 5.06 4.49 
32 5.47 5.02 4.66 
36 5.47 5.01 4.76 
40 5.45 4.99 4.77 
 
Table 6.4 Comparison of the simulated power (%) for various  n values under )25.1log(* =θ , 
05.012 =− PP , and 2.0=σ  when ijkε  ~ ( ) ( )21 ,03.0 )7.0(,07.0)7.0( σσ −≤+⋅≥ NUINUI   
n σσσσ == 21 ,2  σσσ == 21  σσσσ 2, 21 ==  
20 53.10 82.30 22.30 
24 63.15 88.71 33.17 
28 70.81 92.82 43.37 
32 76.81 95.47 51.91 
36 81.34 97.15 59.16 
40 85.02 98.24 65.37 
6.4 Impact of non-normality of the response variable on the type I error rate and 
expected sample size for the two-stage study described in Chapter 5.  
 
In this section, we simulate the within-subject difference in the response variable 
between the test and the reference from the linear mixed effect model in Section 5.2 
with non-normal distributed errors for a sample size of •1n . From this, we obtain the 
sample variance 21S . Using 
2




for the second stage. Then we simulate within-subject differences in the response 
variable for •2n subjects from the linear mixed effect model in Section 5.2 with non-
normal distributed errors. The critical value ( 05.0u ) is 1.715 when •1n =20. Last we 
compare the type I error rate and expected sample size for the two-stage stage study 
under non-normality to the corresponding type I error rate and expected sample size 
under normality.  
6.4.1 Simulation scheme 
 
Again we simulate the within-subject difference in the response variable between 
Period 2 and Period 1 for each subject in each sequence. Let likd denote the within-
subject difference in the response variable for Subject k between the period 2 and 
period 1 in Sequence i at Stage l. So ( ) kikiiik PPd 1212*11 1 εεθ −+−+−= + ,  k=1,2…, in1 . 
( ) kikiiik PPd 1212*12 1 εεθ −+−+−= + , k= 11 +in ,…, ii nn 21 + . 
The simulation scheme is described as follows. 
1) Simulate ijkε  from the non-normal distribution, e.g., t(5), ∀ i=1, 2, j=1, 2 and 
k=1,.., in1 . 






































4) Calculate the new total sample size ( 21 nn + ) from the power function (5.2) 
assuming that 9.00 =p , 05.0




0S . If 02 =n , then stop 
here. Otherwise continue to next step. 
5)  Simulate ijkε  from the non-normal distribution, e.g., t(5), ∀ i=1, 2, j=1, 2 and 
k= 11 +in ,…, ii nn 21 + . Note that ( ) 112121 2/ nnnn −+=  and 
( ) 122122 2/ nnnn −+= . 

















































































































i , and 
( ) ( )212211 /ˆˆˆ nnDnDnD ++= . 











































DT θ   






then pass=1. Otherwise pass=0. 
12) Repeat Steps 1 to 11 many times, for example 50,000 times, to calculate the 
percentage of rejecting the 0H under the 0H  in (5.1) if )25.1log(
* =θ  or 




Below we investigate the impact of non-normality of the response variable on the 
type I error rate and expected sample size.  
6.4.2 Impact of non-normality of the response variable on the type I error rate and 
sample size for the two-stage study in Chapter 5 
 
1. Type I error rate  
We used 105 simulation replicates in this section, so the simulation standard error 
is 0.0007. From Table 6.5, we can see that the type I error rates using our two stage 
approach when ijkε  follows ( )5t⋅σ  or ( )56.0 tσ  are similar to those under normality. 
It also shows that the type I error rates when ijkε  follows ),1,0( ςσ SN⋅ , and 
( ) ( )21 ,03.0 )7.0(,07.0)7.0( σσ −≤+⋅≥ NUINUI  are smaller compared to those under 
normality. The type I error rates for statistical analyses of the two-stage data when 
ijkε  follows the mixture of 2 normal variables are above 0.05 and larger than those 
under normality for 25.0=σ .  Clearly it is clear that our proposed critical values for 
statistical analyses of the two-stage data are robust to non-normal distribution for 









Table 6.5 Comparison of the estimated type I error rates (%) from simulations for various σ values 
with 05.0u =1.715 for 201211 == nn  if ijkε  follows ( )5t⋅σ , ( )56.0 t⋅σ , ),1,0( ςσ SN⋅ , and 
( ) ( )21 ,03.0 )7.0(,07.0)7.0( σσ −≤+⋅≥ NUINUI  
 
σ  ijkε  
( )σ,0N
  











5.0−=ς  5.0=ς  σσσ 22 21 ==  σσσ == 21  
0.25 4.99 4.77 4.79 5.03 4.97 5.34 5.09 
0.3 4.92 4.86 4.64 4.49 4.61 5.05 4.99 
0.35 4.70 4.64 4.68 4.66 4.74 4.93 4.74 
0.4 4.54 4.56 4.58 4.71 4.88 4.75 4.44 
0.45 4.65 4.44 4.41 4.78 4.67 4.97 4.56 
 
2. Sample size 
Table 6.6 shows that the expected sample sizes when ijkε  follows ( )5t⋅σ  , 
( )56.0 tσ , or ),1,0( ςσ SN⋅  are much larger than those under normality assumption.  
The expected sample sizes when ijkε  follows ( )56.0 tσ  are slightly larger than those 
under normality assumption.  It also shows that the expected sample sizes when ijkε  
follows a mixture of 2 normal variables, in which the variability of a subpopulation is 
twice as large as that of the majority of the population, are larger than those under 
normality. The expected sample sizes are similar when ijkε  follows a mixture of 2 








Table 6.6 Comparison of the expected sample sizes from simulations for various σ values with with 
05.0u =1.715 for 201211 == nn  if ijkε follows ( )5t⋅σ , ( )56.0 t⋅σ , ),1,0( ςσ SN⋅ , and 
( ) ( )21 ,03.0 )7.0(,07.0)7.0( σσ −≤+⋅≥ NUINUI  
σ  ijkε  
( )σ,0N
  











5.0−=ς  5.0=ς  σσσ 22 21 ==  σσσ == 21  
0.25 40 62.2 43.6 40.8 40.8 40.0 40.0 
0.3 40.1 88.4 54.7 48.3 48.3 41.9 40.1 
0.35 42.0 119.1 43.2 63.4 63.3 49.6 42.3 
0.4 49.0 154.8 49.9 82.1 82.1 62.5 49.6 
0.45 60.3 195.8 60.7 103.4 103.6 78.1 60.8 
 
6.5 Discussion and conclusions 
 
For TOST in the one stage design, our sensitivity analyses show that the type I 
error rates are not inflated when errors are distributed as the ( )5t⋅σ  or ( )10t⋅σ , or 
),1,0( ςσ SN⋅ if the true mean difference is log(1.25) but the powers under the ( )5t⋅σ  
or ( )10t⋅σ  for 25.0=σ  are smaller compared to those under normality. However the 
type I error rates under the mixture of two normal variables can be above 5% or 
below 5% or equal to 5% depending on the magnitude of the variance of 
subpopulation relative to that of the majority of the population. The resulting power 
under the mixture of two normal variables is much smaller when the variance of 
subpopulation is not equal to the variance of the majority of the population than those 





For the two-stage study, the type I error rates are robust if when errors are random 
variables distributed as ( )5t⋅σ , ( )56.0 tσ , and ),1,0( ςσ SN⋅  under various σ  values 
shown in Tables 6.5 and 6.6 if the true mean difference is log(1.25). The type I error 
rates for two-stage study are 5.34% for a mixture of two normal variables such as 
( ) ( )21 ,03.0 )7.0(,07.0)7.0( σσ −≤+⋅≥ NUINUI  , σσσ 22 21 == , if the overall mean is 
not mis-specified and 25.0=σ  The expected sample size for all non-normal 




Chapter 7  Final conclusions and recommendation 
This dissertation attacked three problems related to the statistical hypothesis 
testing in bioequivalence studies. First we investigated normality assumption for the 
response variable (log(AUC) or log(Cmax)) from the simulated concentration-time 
profiles for a large number of subjects. Second, we presented the exact power formula 
and the sample size calculation for planning a fixed sample size bioequivalence study. 
Third, we developed simpler test statistics and obtained the exact critical values, 
which these simpler test statistics are compared to, for the two-stage study in the new 
unblinded sample size re-estimation procedure.  
7.1 Summary and conclusions  
 
In Chapter 2, we simulated the concentration-time profiles from the two-stage one 
(or two) compartment models and multiplicative measurement errors. Comparing the 
histogram of the standardized response variable (log(AUC) or log(Cmax)) for a large 
sample with the standard normal density curve under many different parameter 
combinations revealed that the sampling distribution of the standardized log(AUC) 
often had heavy tails. The sampling distribution of log(Cmax) was skewed either to 
the left or to the right and was not robust to many perturbations studied in Chapter 2. 
For TOST in the one stage design, our sensitivity analyses in Chapter 6 showed that 
the type I error rates were robust when errors were distributed as ( )5t⋅σ  , 
( )56.0 t⋅σ , ( )10t⋅σ , or )5.0,1,0(SN⋅σ , which closely mimicked the empirical 
distributions from simulations in Chapter 2, if the true mean difference is log(1.25).  




under normality. Type I error rates were inflated if there was a subgroup responding 
differently to the test product from the majority of the population.  
In Chapter 3, the two explicit power functions for the power approach and two 
one-sided tests procedure provided the fundamental understanding of the difference 
between the two one-sided tests procedure and the power approach. We concluded 
that the power approach in practice usually consisted of testing the hypothesis of no 
difference at level 0.05 and a lack of significance was often used to incorrectly infer 
equivalence. In Chapter 4, we derived the exact power formula for two one-sided 
tests. From the exact power function, we calculated the exact powers and sample 
sizes in all bioequivalence study settings, including those for unequal variance of the 
test and reference products. The comparison between the exact power and a previous 
approximate power approach showed this approximate method could significant 
underestimate the power for many practical settings. Accurate numerical calculation 
of exact power could be readily obtained with our R code for the widely used free R 
software package. 
In Chapter 5, our simulation showed that not much information was lost if the 
simpler test statistics ( )*22*21,TT  was used instead of ( )2221,TT . In our unblinded sample 
size re-estimation procedure, we calculated the new sample size using the exact 
power function derived in Chapter 4 in which the sample variance from Stage 1 data 
replaced the true variance. To assure the experimentwise type I error at the nominal 
level α, we presented the exact power function for one stage study in which we 




two-stage study in which we compared simpler test statistics ( )*22*21,TT  with the exact 
critical values ( )αα uu −, . The positive exact critical value, αu , was derived as the 
largest value of u for which  the following condition holds: that supremum of the 
probability of rejecting the null under the null in the composite hypothesis testing 
(5.1) is exactly α. We proved that the maximum of this probability occurs within the 
carefully chosen range for V and u. We developed a numerical analysis for calculating 
the exact type I error rates and bounded the numerical and computation errors for 
approximating the exact type I error rates at grid points and quantified the maximum 
difference for any subinterval between two adjacent grid points in calculating exact 
type I error rate. To make sure the size of the sample size re-estimation procedure at 
the nominal level α- 410− , we chose the sufficient number of grid points in the 
carefully-chosen interval so that the sum of all levels of errors is about 410− . 
For the sample size re-estimation study design, the type I error rates and expected 
sample sizes are robust when errors are random variables distributed as ( )5t⋅σ , 
( )56.0 tσ , and )5.0,1,0(SN⋅σ  under various σ  values.  Type I error rates are inflated 
if errors are distributed as the mixture of 2 normal distributions. 
7.2 Recommendation for future work 
This work mainly focused on statistical methods in bioequivalence studies under 
normality. Our conclusions about the distributional assumption for log(AUC) or 
log(Cmax) should be scrutinized further with many real cases. If normality of 
log(AUC) or log(Cmax) cannot be assumed, statistical methods using robust statistics 




maximum was the global one, then there could be more work for theoretical 
evaluation of the sample size re-estimation procedure. Adaptive design combining the 
use of the group sequential method and the sample size re-estimation method should 
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Index of Notation 
AUC: Area under the concentration-time curve 
Cij: Concentration at the jth time (tij) for the ith subject 
Cmax: Maximum concentration in the concentration profile 
CV: Coefficient variation for untransformed concentration data 
D: Dose amount, mg 
D̂ : Average of the averages of the intra-subject differences in Y between the test and 
the reference for the two sequences 
likd : Difference between Period 2 and Period 1 for Subject k in Sequence i at Stage l, 
l=1,2 
hd : Mean of the period differences of two sequences at Stage l, l=1,2 
eij: Normal random measurement error at the jth time (tij) for the ith subject 
F : Bioavailability fraction  
( )θ,xF : Distribution function 
f(tij, βi): A nonlinear function 
FR: μR 
FT: μT 
ka: Apparent first-order absorption rate constant  
ke: Apparent first-order elimination rate constant 
n1: Number of subjects in Sequence 1 for one-stage study 
n2: Number of subjects in Sequence 2 for one-stage study 
lin : Sample size of the i




•ln : Total sample size ( )21 ll nn + at Stage l, l=1,2 
( )σθ ,*1P : Probability of rejecting the null hypothesis in a two one-sided hypothesis 
tests procedure for a single endpoint 
),( *1 σθ
PowerP : Probability of rejecting the null hypothesis in power approach for a 
single endpoint 
( )VnnP s ,,, 121121 θ : Joint probability of rejecting 0H  in Equation (5.1) under 0H  for 
one-stage study and 01 SS ≤  
( )upVnnP s ,,,,, 0121122 θ : Joint probability of rejecting 0H  in Equation (5.1) under 0H  
for two-stage study ( 02 >•n ) and 01 SS >  
2S : Pooled estimate of the variance of an intra-subject difference in Y 
2
0S : Initial variance value for
22
RT σσ +  from the historical data 
2
lS : Sample variance for
22
RT σσ +  from Stage l, l=1,2 
*S : Pooled variance of Stage 1 and Stage 2, 















tij: The jth sampling time for the ith subject 
Tmax: Time to reach maximum concentration 
*
21T : Test statistics for combined data of Stage 1 and Stage 2  
*
22T : Test statistics for combined data of Stage 1 and Stage 2 
V: 22 RT σσ +  
aV : Apparent volume of distribution 




Y: log(AUC) or  log(Cmax) 
tC
µ : True concentration of a drug  
Tµ : Population mean of Y for the test product 
Rµ : Population mean of Y for the reference product 
ν : Degrees of freedom 
*θ : RT µµ −  
1θ : Lower limit of bioequivalence margin 
2θ : Upper limit of bioequivalence margin 
2
ijσ : Variance of )log( ijC at the jth time (tij) for the ith subject 
2
Rσ : Variance of Y for reference product 
2
Tσ : Variance of Y for the test product 
bi: Normal random vector of inter-subject variation  
ie : Errors of the i
th subject  
( )iig β : Functions of the ith subject 
βi: ( 1×p ) vector of pharmacokinetic parameters 
iR : Variance-covariance matrix of log-transformed data within the ith subject 
γ : Positive vector of population pharmacokinetic parameters 
Σ: Covariance matrix 
 
